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ABSTRACT
Balch, Maria Helen Harley. M.S., Department of Neuroscience, Cell Biology, and
Physiology, Wright State University, 2014. Effects of Delayed Pharmacological
Treatment and Limb Rehabilitation on Infarct Size and Functional Recovery After
Stroke.

Previous studies show a fluoxetine/simvastatin drug combination successfully
reduced infarct size and increased functional recovery when administered 20-26 hours
post-stroke. This project tested the hypothesis that earlier drug delivery at 6-12 hours
post-stroke will improve functional recovery and decrease infarct size, and that limb
rehabilitation will improve functional recovery.
Pre-stroke function was determined in rats, a stroke was induced, and daily
treatment began 6-12 hours post-stroke. Baseline functional deficit was established, and
additional testing over 90 days monitored functional recovery. Limb rehabilitation was
provided for designated animals, and brain analysis measured infarct size.
In animals with no rehabilitation, drug treatment provided better recovery; with
rehabilitation, recovery was similar whether animals received drug treatment or not,
suggesting a drug treatment could replace rehabilitation if needed. Larger infarcts were
also present with earlier drug delivery, implying the possibility of hemorrhagic
transformation due to earlier induction of VEGF expression by our drug combination.
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I. INTRODUCTION

STROKE
Every forty seconds, someone in the United States has a stroke (Centers for
Disease Control and Prevention (CDC): National Center for Chronic Disease Prevention
and Health Promotion (NCCDPHP), Division for Heart Disease and Stroke Prevention
(DHDSP), 2013). Strokes affect nearly 795,000 people each year, and 610,000 of those
cases occur in patients who have not previously had a stroke (CDC: NCCDPHP, DHDSP,
2013). Census data analysis suggests that incidence of stroke each year will double by
2050 (Howard and Goff, 2012). Stroke is also a leading cause of serious long-term
disability in the United States (CDC: NCCDPHP, DHDSP. 2013; Go et al, 2014). When
accounting for healthcare expenses, cost of medications, and lost productivity, studies
estimate the national annual cost of stroke at $38.6 billion (CDC: NCCDPHP, DHDSP,
2013).
The fourth leading cause of death (Towfighi and Saver, 2011; Murphy et al,
2013), strokes kill almost 130,000 Americans each year (CDC: NCCDPHP, DHDSP,
2013). Approximately one out of every 19 deaths is caused by a stroke (Go et al, 2014),
with someone dying of a stroke every four minutes (CDC: NCCDPHP, DHDSP, 2013).
In addition, the Acute Cerebrovascular Care in Emergency Stroke Systems (ACCESS)

1

study reported that only half of the American population has timely access to a primary
stroke center (PSC) (Albright et al, 2010).
Stroke clearly stands as one of the most significant health issues in the United
States (Hall et al, 2012). Injury following a stroke develops via a multifaceted sequence
of pathophysiological events (Dirnagl et al, 1999). In order to comprehend these events
and develop treatment options, the immediate and post-stroke conditions within the brain
and the associated mechanisms must be understood (Hossmann, 2006). Stroke research
provides a means to reach this understanding and is thus essential to the health of the
country.

Types of Stroke
There are two major types of stroke: ischemic and hemorrhagic. Both types of
stroke, whether caused by a clot or bleeding, can result in damage and death of cells in
the brain.
Ischemic strokes account for 87 percent of stroke cases (American Heart
Association (AHA)/American Stroke Association (ASA), 2012) and occur when a vessel
that supplies blood to the brain is blocked by a clot. Ischemic strokes can be either
thrombolic – where a clot forms within a vessel in the brain – or embolic – where a clot
forms in a vessel elsewhere in the body and moves to the brain (National Stroke
Association, 2014b).
Unlike ischemic strokes, hemorrhagic strokes do not involve a blood clot.
Instead, a vessel bursts or leaks, causing damage and increased pressure on brain tissue.
Aneurysms are ballooning regions of weak-walled blood vessels, while arteriovenous
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malformations (AVMs) are clusters of abnormally-formed vessels (AHA/ASA, 2012).
Both aneurysms and AVMs are capable of rupturing and causing hemorrhagic strokes.
When a ruptured vessel bleeds into the brain, the event is called an intracerebral
hemorrhagic stroke. Conversely, when a ruptured vessel bleeds outside of the brain into
the subarachnoid space, the event is called a subarachnoid hemorrhagic stroke (National
Stroke Association, 2013).
In addition to ischemic and hemorrhagic strokes, transient ischemic strokes
(TIAs), also known as mini-strokes, can occur. TIAs exhibit similar symptoms as
ischemic strokes, but the effects are brief because the clot only temporarily blocks the
vessel (AHA/ASA, 2012).

Current Pharmacological Treatment for Stroke
Recombinant tissue plasminogen activator (tPA) was approved for use treating
ischemic stroke in 1996 (Zivin, 2009) and remains the only Food and Drug
Administration (FDA)-approved treatment for stroke (AHA/ASA, 2013). Blood clots
form when activated platelets aggregate onto fibrin threads. Plasmin is a protease
capable of breaking down the fibrin meshes via fibrinolysis. The inactive form,
plasminogen, must be activated by a plasminogen activator (PA). One such PA is tPA.
Because timely reperfusion is imperative to save the ischemic brain tissue (Zhang et al,
2012), recombinant tPA was developed as a pharmacological treatment for ischemic
stroke (National Institute of Neurological Disorders and Stroke (NINDS), 1995), acting
by breaking down the clot and resulting in recanalization of the previously-occluded
blood vessel (Gravanis and Tsirka, 2008).

3

A precise window of administration exists when using tPA, as a patient must
present to the hospital for treatment within three hours post-stroke (Clark et al, 1999;
Hacke et al, 2004; NINDS, 1995) (up to four-and-one-half hours in certain qualifying
patients) (Stemer and Lyden, 2010). If the three-hour post-stroke treatment window has
passed, a patient is considered ineligible to receive the drug. Unfortunately, this is often
the case with patients because they are unable to recognize the symptoms or arrive at a
hospital in time (Y. Li et al, 2014). Though previously-reported national averages for
patients receiving tPA treatment vary (AHA, 2009; Reeves et al, 2005), it is estimated
that less than five percent of ischemic stroke patients are able to be treated with tPA
(California Pacific Medical Center, 2013).
tPA administration is time-sensitive because of the possibility of hemorrhagic
transformation, or secondary bleeding after an initial ischemic stroke has occurred
(Jickling et al, 2014; Chapman et al, 2014; National Stroke Association, 2014a). Some
studies suggest harmful effects of tPA arise beyond the approximate three-hour
post-stroke mark because of its ability to activate matrix metallo-proteinase-9 (MMP-9),
which is an enzyme that degrades extracellular matrix (ECM) components (Zhao et al,
2004) and contributes to blood-brain barrier (BBB) breakdown (Chaturvedi and
Kaczmarek, 2013). Other studies suggest involvement of low-density lipoprotein (LDL)
receptor-related protein (LRP) (Yepes et al, 2003) or that both LRP and MMP-9
mediators contribute to hemorrhagic transformation with tPA (Ortolano and Spuch,
2013). Mast cell degranulation and caspase-8 have also been investigated as mediators of
tPA toxicity (Ishrat et al, 2012). Many studies speak to the importance of understanding
the deleterious effects of tPA on cytotoxicity, cerebral edema, neurovascular unit
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permeability, and intracranial bleeding (Armstead et al, 2006; Sappino et al, 1993;
Yepes et al, 2009). Regardless of the mechanism, it is clear that the undeniable
thrombolytic benefits of tPA are compromised due to administration restrictions and
possible brain hemorrhage, thus making it available to only a small minority of patients.
It has been stated that the argument whether tPA should be considered
neuroprotective or neurotoxic could continue indefinitely (Gravanis and Tsirka, 2008).
Evidence is certainly shown for both cases. Research is aimed at the goal of treating
more ischemic stroke patients with tPA. Combination therapies coupling tPA with other
neuroprotective agents are being tested and explore mediators such as MMP inhibitors,
LRP antagonists, mast cell stabilizers, platelet inhibition, free radical scavengers,
neuroserpin, and estrogen therapy. These studies have shown a reduction in vascular
damage or hemorrhagic transformation and, therefore, suggest tPA use can continue,
more patients can benefit, and negative side effects can be avoided (Ishrat et al, 2012;
Zhang et al, 2012). Studies are also attempting to identify ways to accurately predict the
risk of hemorrhagic transformation in ischemic stroke patients (Shinoyama et al, 2013).

Endogenous tPA
While recombinant tPA was developed as a pharmacological treatment for
ischemic stroke (NINDS, 1995), tPA itself is produced naturally in the human body. It is
expressed in both developing and mature brain tissue in neurons and microglia. Besides
its role in fibrinolysis and preservation of nonthrombogenic vascular surfaces (Bednar
and Gross, 1999; Lucking et al, 2013), it is suggested that endogenous tPA mediates
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neuronal death and microglial activation following excitotoxic injury as well (Ishrat et al,
2012).
Research has shown that cerebral ischemia increases levels of endogenous tPA
(Copin et al, 2011), and this increase induces opening of the BBB (Yepes et al, 2003).
While normal tPA production may be a function of all endothelium (Ishrat et al, 2012),
the origin of tPA in brain tissue after injury to the brain is not well described (Zhao et al,
2004).
As previously discussed, tPA administration presents with the risk of hemorrhagic
transformation. Some publications propose endogenous tPA contributes to hemorrhagic
transformation by enhancing MMP-9 expression or proteolytic activation (Tang et al,
2010; Umemura, 2005). However, the precise involvement of endogenous tPA in
hemorrhagic transformation is unclear.

Rehabilitation and Stroke
Because stroke is the leading cause of adult disability in the United States,
rehabilitation therapy for stroke patients is of utmost importance. Occupational therapy
assists with relearning everyday activities, and speech language pathology helps patients
rebuild speaking skills. Because depression, frustration, and anxiety are commonly
observed in stroke patients, psychological treatment may also be involved. Of all
available therapies, physical therapy is considered the cornerstone of the rehabilitation
process and aims to restore movement, balance, and coordination (NINDS, National
Institute of Health (NIH), 2014).
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Brain-Derived Neurotrophic Factor (BDNF)
Neurotrophins are a family of growth factors associated with neuronal growth and
survival (Miller and Kaplan, 2001). One such neurotrophin, BDNF, is widely distributed
in the central nervous system (Binder and Scharfman, 2004). In addition to stimulating
neurogenesis (Schäbitz et al, 2007), BDNF promotes neuroplasticity (Madinier et al,
2013) and assists with learning and memory (Bekinschtein et al, 2008; Binder and
Scharfman 2004; Ploughman et al, 2009). Aside from its function in supporting existing
neurons, BDNF also appears to play a crucial part in brain injury and recovery.
A gradual increase in astrocytic expression of neurotrophic factors has been
observed in the brain after ischemic injury. Studies suggest this increase may protect
these brain regions from further damage and facilitate brain repair (Kleim et al, 2003).
Specifically, BDNF initiates anti-apoptotic mechanisms, reduces infarct size, and
decreases instance of secondary neuronal cell death (Schäbitz et al, 2007).
After an ischemic event, rehabilitation is necessary to support brain plasticity
(Kleim et al, 2003). While neuroplasticity engages multiple signaling pathways, BDNF
has been shown to play a critical role in motor learning and recovery through
rehabilitation post-stroke (Mang et al, 2013; Ploughman et al, 2009). Following stroke,
forced use and rehabilitation of an impaired limb improves functional recovery
(Livingston-Thomas et al, 2014), and, in turn, stimulates increases of BDNF in the brain
(MacLellan et al, 2011). Interestingly, exercise independent of ischemic injury also
results in increased levels of BDNF as well as other defenses against cell death
(MacLellan et al, 2011; Ploughman et al, 2009).
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Adult Neurogenesis
The term neurogenesis refers to the growth and development of new neurons.
This process is most active during embryonic development, and until 1962, it was
believed the adult nervous system was fixed, incapable of regeneration. However, it is
now known that neurogenesis can occur at two locations in the adult brain: the
subventricular zone (SVZ), lining the lateral ventricles, and the subgranular zone,
forming part of the dentate gyrus of the hippocampus (Mandal, 2014; Nogueira et al,
2014). A resident population of neural progenitor cells provides the source of new
neurons (Elder et al, 2006).
A microtubule-associated protein (MAP) known as doublecortin (DCX) assists
with the young neuronal migration into cortical layers of the brain during embryological
development. DCX expression in areas with extended neuronal recruitment allows this
endogenous protein to be used as a marker for adult neurogenesis (Vellema et al, 2014).
Stroke has been shown to trigger neurogenesis, not only in the SVZ for example,
but also in areas of the brain that do not exhibit neurogenesis under normal conditions. It
is possible that radial microglia are involved with guiding migration of neuroblasts to the
ischemic brain tissue. There is also evidence that neurogenesis is linked to angiogenesis
(Seki et al, 2011), which is the process that forms new blood vessel branches from
existing vessels (Mayes, 2006).
The hope of assisting cell replacement after an ischemic event has directed some
stroke research to focus on drug therapy that may stimulate neurogenesis.
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STROKE RESEARCH
Because stroke persists as one of the most substantial health issues today
(Hall et al, 2012), much research centers on developing pharmacological treatments for
stroke. With ischemic stroke accounting for almost 90 percent of strokes (AHA/ASA,
2012), and with a narrow – and many times unreachable – window for tPA administration
(Clark et al, 1999; Hacke et al, 2004; NINDS, 1995), a treatment option available after
three hours post-stroke is ideal.

Animal Model
When developing an animal model for ischemic stroke research, features similar
to those in humans must be considered so the outcomes can be addressed with the least
possible limitations. Biological factors, physiological reactions, and pathological
implications must be reviewed (Casals et al, 2011).
The most relevant animal models for stroke research are rodents or lagomorphs,
such as rabbits (Casals et al, 2011). Rats and mice are most often used (Howells et al,
2010), as their cerebrovasculature closely matches that of higher organisms (Ginsberg
and Busto, 1989). Rodents also present similar Circle of Willis collateralization and
variation to that found in humans (Howells et al, 2010; Mergenthaler and Meisel, 2012).
This is an important consideration when understanding how the brain responds to stroke
induction, depending on the method used, and how the brain responds to treatment.
Previous studies in our laboratory found that Sprague Dawley rats had better
blood vessel collateralization than the Long Evans strain. When the same amount of
endothelin was injected into both rat strains, a much smaller infarct was produced in the
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Sprague Dawley strain, suggesting there is better blood vessel collateralization in the
cortex.
Earlier studies in our laboratory used Long Evans rats. It was noted, however,
that their blood vessel collateralization does not closely match that in humans. In LongEvans rats, endothelin was injected to either side of the forelimb motor cortex, causing
injury but not complete infarction of this important center. With our drug treatment, fast
recovery of forelimb motor function was observed within 30 days, most likely because
the tissue was only injured rather than killed. In addition to these noted concerns, data
suggest that Long Evans rats may be more susceptible to damage in the hemisphere
contralateral to the injury site than are Sprague Dawley rats (Tan et al, 2009).
Sprague Dawley rats are now used in our laboratory instead because they much
more closely match human brain collateralization. To address the recovery matter, the
location of stroke induction was changed to destroy the forelimb motor cortex itself
rather than affect the tissue surrounding it. A lasting deficit is now attainable in an
animal model that more closely relates to humans; this should provide a better
translational approach.
Our rat subjects are all female because the male rats are >60 g heavier than the
females (Casals et al, 2011) and will not fit in the functional test apparatus (Montoya
Staircase, Lafayette Industries; 400 g limit). The female rats used in this study, at 10 to
12 months of age, weighed approximately 320-385 g.
Though no single animal model can fully represent the variables affecting human
ischemic stroke patients (Bacigaluppi et al, 2010; Howells et al, 2010), studies suggest
the lack of translation lies not completely with the choice of animal model but in how
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such models and their resultant data are applied (Howells et al, 2010). Most often, stroke
research is conducted using young animals. However, human stroke patients are
typically elderly and may present other health concerns (Bacigaluppi et al, 2010; Casals
et al, 2011). In addition, young brains react differently to stroke (Casals et al, 2011).
Our study sought to eliminate this limitation by using older animals, aged 10 to 12
months, which is approximately middle-aged for a rodent.

Induction Model
Several induction models have been introduced in stroke research. Many of the
models are successful in following the condition found with human stroke patients in
relation to large artery occlusion. Still, other models result in extremely large infarcts
that may not imitate instances of the most common, treatable human strokes (Carmichael,
2005). With human ischemic strokes typically only affecting approximately 5% of total
brain volume (Brott et al, 1989), it is important to find a model that best matches human
ischemic stroke.
Most frequently used is mechanical occlusion of the proximal middle cerebral
artery (MCA) (pMCAo). This large-vessel occlusion produces a large infarct and is
usually achieved by inserting a silicon-coated nylon suture into the internal carotid artery
to the circle of Willis to occlude the MCA at its source. For a more restricted occlusion
of superficial vessels, mechanical occlusion of the distal MCA (dMCAo) can be
performed. This small-vessel occlusion is accomplished by exposing and altering
superficial MCA branches via a craniotomy (Bacigaluppi et al, 2010). One study showed
most MCAo models produce infarcts between 21-45% of the affected cerebral
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hemisphere, and the dMCAo model specifically produces smaller infarcts than the
pMCAo model, with infarct sizes of approximately 14-25% of the affected hemisphere.
Still, these models more closely mimic large-volume or hemorrhagic strokes in humans
rather than typical ischemic stroke when reviewing infarct size (Carmichael, 2005).
Another model for stroke induction involves intravenous injection of a
photosensitive dye. Once injected, photothrombosis is induced when the brain is
illuminated trans-cranially and the irradiated tissue coagulates. While this model can
produce precise small strokes (Bacigaluppi et al, 2010), the dye itself can damage the
endothelium (Carmichael, 2005). In the case where a drug that targets endothelial cells is
being studied for use in stroke treatment, this model would not be appropriate.
Cerebral veins and sinus thrombosis (CVT) is a disorder affecting younger adults
or children more often than arterial stroke. A model for inducing CVT involves
occluding the superior sagittal sinus, mechanically or thermally damaging the superior
sagittal sinus, or photothrombosis of the dorsal cerebral veins (Bacigaluppi et al, 2010).
Because this study seeks to research the most common instance of ischemic stroke in
humans, this model is not fitting.
Some models have been designed to specifically mimic the effects of an arterial
blockage by a blood clot. Thrombotic occlusion is obtained by injecting blood clots,
thrombin, or synthetic macrospheres into the MCA or internal carotid artery to produce a
large infarct like that of permanent pMCAo. To produce smaller, multifocal infarcts,
synthetic microspheres can be used. However, the high variability in infarct size and
results associated with this model have caused a lack of translation to human stroke
(Bacigaluppi et al, 2010).
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Other approaches have been developed in order to gain more control over the size
of the infarct produced. Injecting the potent vasoconstrictor endothelin intracerebrally
produces a focal ischemic infarct by severely reducing blood flow to the affected area.
Though it can be more difficult to precisely localize the lesion, the endothelin model for
producing focal ischemia is easier, faster, and technically simpler than other rat stroke
models (Bacigaluppi et al, 2010).
Our study employs the endothelin model for stroke induction. Endothelin’s
vasocontrictive mechanism induces a stroke in approximately 30 minutes, with lasting
effects for 24 hours before the vasoconstriction releases (Windle et al, 2006). A sure
consequence of stroke is neurodegeneration, which appears early in this model (Wolinski
and Glabinski, 2013). This method has also proven to be easily performed and
reproducible in rats (Bacigaluppi et al, 2010). Because of the ability to produce smaller,
more controlled infarcts, in addition to its ease of use, confirmed repeatability, and
accuracy in generating ischemic stroke, the endothelin model was chosen for our study.

PHARMACOLOGICAL TREATMENT DESIGN
In order to propose a delayed pharmacological treatment for stroke, several
standards must be established. The individual drugs involved, the proper dosage of each
drug, and the ideal timeframe for drug delivery post-stroke must all be defined.
Previous studies in our laboratory have reviewed combinations of fluoxetine,
simvastatin, and ascorbic acid in hopes of optimizing the dose of essential constituents
(Corbett et al, 2013). Combination therapies have proven to be more effective than a
single drug in treating many health concerns, from depression (Blier et al, 2010) to
cancer (F. Li et al, 2014), and from diabetes (Tosi et al, 2003) to human
13

immunodeficiency virus (HIV) (Pakker et al, 1998). There was already work in the
literature showing that fluoxetine alone (Schäbitz et al, 2007) and simvastatin alone
(Rodríguez-Yáñez et al, 2008) increase neurogenesis, but no one had ever tested the
combination. Information on each drug, its class, and the final drug combination is
presented below.

Selective Serotonin Reuptake Inhibitors (SSRIs) and Stroke
Fluoxetine belongs to a group of drugs known as SSRIs. SSRIs act to treat
depression by inhibiting presynaptic reuptake of serotonin. This inhibition increases the
availability of serotonin at the synaptic cleft (Costagliola et al, 2008).
In addition to its ability to help manage depression, SSRIs may improve recovery
after stroke. SSRIs appear to improve neurological impairment and disability; this
finding holds true even in patients who are not depressed (Mead et al, 2012).
Additionally, SSRIs inhibit platelet aggregation, decrease ischemic risk, protect against
inflammatory neurotoxicity, and stimulate neuroplasticity, neurogenesis, and
angiogenesis (Rao and Andrade, 2011).
Many antidepressants have been reviewed for their ability to treat depression and,
separately, to assist with stroke recovery. For the treatment of depression alone, studies
compared the use of fluoxetine to that of other SSRIs, tricyclic antidepressants (TCAs),
and heterocyclic and related antidepressants. Significant differences surfaced regarding
the efficacy and tolerability of the drugs reviewed for depression treatment, but the study
concluded uncertainties in the application, and no clinical implications could be drawn
(Cipriani et al, 2005; Magni et al, 2013). However, another study compared the use of
SSRIs to TCAs for stroke treatment and found that SSRIs significantly reduced the risk
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of stroke as compared with TCAs (Lee et al, 2013). While certain antidepressants did not
stand out against others in terms of treatment for depression, SSRIs presented obvious
benefits for stroke recovery.

Fluoxetine
When evaluating SSRIs for stroke treatment, studies have used fluoxetine,
sertraline, paroxetine, citalopram, or escitalopram (Mead et al, 2013b). Although it
seems acceptable that all SSRIs would have similar effects, most of the stroke research
using SSRIs has been conducted using fluoxetine (Rao and Andrade, 2011).
Fluoxetine crosses the BBB (Warren, 2012) and increases expression of BDNF,
which plays a role in cognitive recovery (Liu et al, 2013) and neurogenesis
(Schäbitz et al, 2007). Fluoxetine also greatly improves motor recovery with ischemic
stroke patients (Chollet et al, 2011; Chollet et al, 2013; Marquez-Romero et al, 2013) and
results in less disability (Cramer, 2011). Studies have followed patients through their
recovery and have seen enhanced motor improvement after three months post-stroke
(Chollet et al, 2011; Cramer, 2011). Such mechanisms are believed to involve
modulation of brain plasticity (Chollet et al, 2011).
Furthermore, neuroprotective effects accompanied the advances in motor
recovery. Fluoxetine’s neuroprotection may be associated with its anti-inflammatory
effects. Microglial activation, expression of proinflammatory markers, and neutrophil
infiltration were all suppressed in brain tissue after being treated with fluoxetine poststroke, suggesting that fluoxetine protects the brain against ischemic injury (Lim et al,
2009).
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In addition to neurogenesis promotion via BDNF, anti-inflammatory effects, and
reduced motor cortex excitability, fluoxetine may act by inducing expression of vascular
endothelial growth factor (VEGF). VEGF is a mediator of neurogenesis,
neuroprotection, and angiogenesis after ischemia. By upregulating VEGF – an action
specific to SSRIs, as TCAs do not affect the VEGF pathway – fluoxetine facilitates other
avenues of brain recovery after stroke (Gaillard and Mir, 2001).
Some debate exists regarding the efficacy of fluoxetine at different doses (Zhu
BG. et al, 2012) as well as possible risks and interactions. SSRIs block serotonin uptake
by platelets, which impairs the platelet hemostatic response. Some have expressed
concern about a possible increase in bleeding risk when used as stroke treatment.
However, only epidemiologic studies of gastrointestinal bleeding have been performed,
and the study concluded that the data are too limited to permit interpretations about
influences on stroke (Andrade et al, 2010). Additionally, there are postulated interactions
of fluoxetine with other drugs. Studies suggest fluoxetine interacts with the anticoagulant
warfarin, which is prescribed to prevent blood clot formation (Dent and Orrock, 1997);
the anticonvulsant diazepam, which is prescribed for patients who experience seizures
after a stroke (Dent and Orrock, 1997); and the antiplatelet drug clopidogrel, which is
often prescribed after a stroke for secondary prevention (Gonzenbach et al, 2011), or
efforts used to prevent future stroke in a patient who has already had a stroke.
Unfortunately, most of these interactions are not well defined or established (Dent and
Orrock, 1997; Gonzenbach et al, 2011).
Studies suggest larger trials will help determine whether post-stroke SSRI
administration should be routine (Mead et al, 2012; Mead et al, 2013a). Current clinical
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trials using fluoxetine to study the implications of SSRI use in stroke recovery include
Fluoxetine or Control Under Supervision (FOCUS) in the United Kingdom, Assessment
oF FluoxetINe In sTroke recoverY (AFFINITY) in Australia, and Efficacy oF Fluoxetine
- a randomisEd Controlled Trial in Stroke (EFFECTS) in Sweden (Mead et al, 2013a).

Statins and Stroke
Simvastatin belongs to a group of drugs called statins. Statins help lower
cholesterol by inhibiting the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A (HMGCoA) reductase, which catalyzes a rate-limiting step in the biosynthesis of cholesterol.
By reducing levels of LDL cholesterol in plasma, statins serve to decrease cardiovascular
risk (Hernández-Perera et al, 1998).
In addition to their role in cholesterol metabolism, studies suggest statins possess
cholesterol-independent pleiotropic effects that improve endothelial function, inhibit
thrombogenic response, stabilize atherosclerotic plaques, and decrease inflammation and
oxidative stress (Liao and Laufs, 2005). Statins also provide neuroprotection against
ischemic injury, making them an important candidate in stroke treatment (HernándezPerera et al, 1998; Miedema et al, 2010; Stepień et al, 2005).
Though the neuroprotective mechanisms of statins are only partially understood
(Sierra et al, 2011), it is believed that changes in inflammation, platelet aggregation,
immune response, glutamate metabolism, and apoptosis are involved (Rodríguez-Yáñez
et al, 2008). Statins provide protection against ischemic injury by upregulating
endogenous tPA (Asahi et al, 2005). Statins have also been shown to protect against
vascular remodeling, an adaptive process that can negatively contribute to vascular
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pathophysiology (Dzau and Gibbons, 1993), by suppressing the Rho/Rho-kinase pathway
(Ma et al, 2012). Inhibition of isoprenoids, which serve as lipid attachments for
intracellular signaling molecules, may also mediate some of the pleiotropic effects (Liao
and Laufs, 2005).
Moreover, statins promote angiogenesis, formation of new synapses, and
neurogenesis (Rodríguez-Yáñez et al, 2008). One avenue through which statins initiate
neurogenesis and protect against ischemic injury is by upregulating endothelial nitric
oxide synthase (eNOS) (Asahi et al, 2005; Mital et al, 2000). Nitric oxide (NO) is
normally produced in the brain by the neuronal isoform of NOS and negatively regulates
precursor cell proliferation. However, in the injured brain, NO overproduction actually
promotes neurogenesis (Estrada and Murillo-Carretero, 2005).
Recent studies show statins consistently reduce the risk of ischemic stroke in
patients (Tuttolomondo et al, 2014) and are recommended to lower the risk of stroke
recurrence or other vascular events after an ischemic stroke (X. Li et al, 2012). Statins
have also been shown to support neurovascular recovery and improve neurological
outcome after intracerebral hemorrhage (Yang et al, 2012).

Simvastatin
Studies have reviewed all statins in order to determine which statin works best to
protect the brain. The nine statins can be divided into three categories: natural or
fungus-derived, semi-synthetic, and synthetic. Data show the natural and semi-synthetic
statins, also known as monacolin J derivatives, are the best contenders for preventing
neurodegeneration. Reasons for this conclusion include a higher potential for BBB
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penetration, the safe manner in which they lower cholesterol in neurons, and observations
regarding protection against cell death in culture. Of the nine total statins, simvastatin,
also a monacolin J derivative, presented as the best option for preventing
neurodegenerative conditions (Sierra et al, 2011).
Because simvastatin is lipophilic (Thelen et al, 2006), it can easily cross the BBB
(Wood et al, 2010) and is more likely to passively diffuse into endothelial cells than
hydrophilic statins (Zhu M. et al, 2012). These properties explain why use of simvastatin
has resulted in improving the function of ischemia-disturbed BBBs (Jiang et al, 2012). In
addition, simvastatin increases BDNF expression (Yang et al, 2012), which, as
previously discussed, works in neuroprotection and reduction of infarct size (Kleim et al,
2003; Schäbitz et al, 2007). Simvastatin also upregulates VEGF, which initiates
angiogenesis (Wu et al, 2008).
In ischemic stroke, high extracellular levels of glutamate overstimulate glutamate
receptors. This overstimulation causes calcium entry into neurons through
N-methyl-D-aspartate receptors (NMDARs), which is a central influence of neuronal
excitotoxicity. Simvastatin has been shown to significantly decrease infarct area after
ischemia and increase expression of protein phosphatase 2A (PP2A). PP2A is a family of
serine-threonine phosphatases controlling multiple cellular processes through negative
signal regulation, including suppression of NMDARs, thus aiding in protection against
neuronal excitotoxicity (Zhu M. et al, 2012).
Simvastatin is believed to influence vascular tone by moderating endothelial
vasoactive factor expression (Hernández-Perera et al, 1998). Simvastatin also increases
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eNOS activity (McGirt et al, 2002), and, as noted earlier, NO overproduction promotes
neurogenesis (Estrada and Murillo-Carretero, 2005).

Simvastatin and tPA
Clinical benefits are observed when administering simvastatin alone or when
coupling simvastatin with tPA. When used together, simvastatin increases the
therapeutic window for tPA and encourages neuroprotection (Lapchak and Han, 2010).
Though some benefits exist, combining simvastatin with tPA is a controversial
topic. Some studies suggest a possible increase in the risk of hemorrhagic transformation
when combining simvastatin with tPA (Laloux, 2014; Scheitz et al, 2014), while others
state that simvastatin reduces tPA-induced hemorrhage (Lapchak and Han, 2010),
decreases neurovascular unit dysfunction (Zhang et al, 2012), and produces no increase
in hemorrhagic transformation risk (Campos et al, 2013). The proper dose of simvastatin
with tPA and window of administration has not yet been determined (Lapchak and Han,
2010).

Pre-Stroke Exposure to Statins
Pre-stroke statin exposure trends toward improved results in ischemic stroke
patients. While patients taking statins did have less severe strokes, the effects were not
significantly different. Nevertheless, results suggest a tendency toward lower stroke
severity and improved outcomes short-term post-stroke (Phipps et al, 2013).

20

Ideal Drug Combination
Because of its pleiotropic actions that improve the disturbed BBB (Jiang et al,
2012), increase BDNF expression (Yang et al, 2012), upregulate eNOS activity (McGirt
et al, 2002), promote neurogenesis (Estrada and Murillo-Carretero, 2005), and aid in
neuroprotection and infarct size reduction (Kleim et al, 2003; Schäbitz et al, 2007),
simvastatin was chosen as a component in this study’s drug combination.
Similarly, fluoxetine was chosen for use in our study due to its ability to stimulate
neurogenesis through BDNF expression (Liu et al, 2013; Schäbitz et al, 2007), improve
motor recovery (Chollet et al, 2011; Chollet et al, 2013; Marquez-Romero et al, 2013),
promote anti-inflammatory effects (Lim et al, 2009), and enhance neuroprotection and
angiogenesis through VEGF expression (Gaillard and Mir, 2001).
Because simvastatin and the eNOS enzyme are both easily oxidized, and because
ascorbic acid is an antioxidant that should help retain normal function in both substances,
asborbic acid was originally reviewed as a possible component of the combination.
However, it was later discovered that the major filler in simvastatin is already ascorbic
acid, so simvastatin and fluoxetine together proved to be the desired combination.
The drug combination used in this study was 5 mg/kg fluoxetine, 1 mg/kg
simvastatin. In the “fluoxetine for motor recovery after acute ischaemic stroke
(FLAME)” clinical trial, a dose of 20 mg fluoxetine was administered post-stroke
(Chollet et al, 2011), which corresponds to an approximate dose in rats of 2.5 mg/kg
(Reagan-Shaw et al, 2007). In humans, a patient is typically started at a dose of 20 mg
fluoxetine; the dose is later increased as needed. Our laboratory’s rat dose of 5 mg/kg
fluoxetine correlates to a human dose of approximately 40 mg/kg, which is well within

21

the normal human dose range of 20-80 mg for this drug (Rx List, 2014a). Two rat doses
of simvastatin have been used in our laboratory’s studies: 0.5 mg/kg and 1 mg/kg. These
rat doses correlate to approximate human doses of 5 mg or 10 mg respectively. These
doses are well within the normal human dose range of 5-40 mg for this drug (Rx List,
2014b).
With the individual drugs comprising the combination outlined and the proper
dosage of each drug defined, the ideal timeframe for drug delivery post-stroke must be
established.

HYPOTHESIS
A previous study noted success with the fluoxetine/simvastatin drug combination
in reducing infarct size and increasing functional recovery when delivered 20-26 hours
post-stroke (Corbett et al, 2013). This study seeks to test the hypothesis that earlier drug
delivery will improve functional recovery and decrease infarct size by determining the
effects of the fluoxetine/simvastatin drug combination when administered at 6-12 hours
post-stroke. This study also seeks to test the hypothesis that limb rehabilitation will
improve functional recovery.

SPECIFIC AIMS
The focus of this study is to determine the effects of the earlier
fluoxetine/simvastatin drug combination delivery on functional recovery and infarct size
as well as define the effects of limb rehabilitation on functional recovery. This work
aims to help identify the prime window of drug delivery for optimum effects on
increasing functional recovery and reducing infarct volume in the ischemic brain.
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Two experiments were preformed to test the hypotheses. Experiment 1 reviewed
earlier drug delivery at 6-12 hours post-stroke. No rehabilitation was included in
Experiment 1. Two groups of animals were defined in this portion of the study:
drug-treated and control.
Experiment 2 reviewed earlier drug delivery at 6-12 hours post-stroke as well,
using the same drug combination and dosage as Experiment 1. Additionally, Experiment
2 included and reviewed a rehabilitation component. Four groups of animals were
defined in this portion of the study: drug-treated with rehabilitation, drug-treated without
rehabilitation, control with rehabilitation, and control without rehabilitation.
To test the hypothesis that earlier drug delivery will improve functional recovery,
pre-stroke function can be established for all animals using the Montoya staircase
functional grasping test. After stroke induction, the animals can be retested to establish a
baseline functional deficit. Following treatment for 90 days, the functional assessment
data will quantify functional recovery, which will be compared between the drug-treated
and control animals to determine whether earlier drug delivery improves functional
recovery. After euthanasia and brain tissue analysis, infarct volume can be calculated for
each animal. Comparison of infarct size in drug-treated animals to control animals will
allow for testing of the hypothesis that earlier drug delivery will decrease infarct size.
This process is followed in Experiment 1.
Like Experiment 1, Experiment 2 analyzes functional recovery and infarct
volume. Unlike Experiment 1, Experiment 2 also tests the hypothesis that limb
rehabilitation will increase functional recovery. In Experiment 2, certain control animals
and certain drug-treated animals are given rehabilitation using reaching shelves outside
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their cages. The functional recovery of drug-treated animals with rehabilitation can then
be compared to that of drug-treated animals without rehabilitation; the functional
recovery of control animals with rehabilitation can be compared to that of control animals
without rehabilitation; and all animals receiving rehabilitation (regardless of drug
treatment) can be compared to all animals not receiving rehabilitation. These
comparisons will allow for the determination of whether rehabilitation increases
functional recovery.
Infarct size and functional recovery data from Experiments 1 and 2 can also be
analyzed to determine if a correlation exists between the two factors. In addition, the
data from this study (Experiments 1 and 2), in which drug delivery is at 6-12 hours
post-stroke, can be compared to the data from the previous study, in which drug delivery
was at 20-26 hours post-stroke. This will provide valuable insight as to the optimum
window for drug delivery and contribute to the current research aim of developing a
treatment for stroke.
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II. MATERIALS AND METHODS
All studies described in this paper were performed in accordance with protocols
approved by the Wright State University Institutional Animal Care and Use Committee
(IACUC).

PRE-STROKE TRAINING
Female Sprague Dawley outbred retired breeder rats aged 10 to 12 months were
trained on Montoya Staircases. The Montoya Staircase (Figure 1) is a functional test that
presents food pellets on a bilateral set of stairs, requiring the rat to crawl onto a raised
platform, extend its forelimbs at increasing distances to reach each stair, and grasp pellets
to retrieve them (Montoya et al, 1991). Three sucrose pellets – some painted with maple
extract – were placed in each of the wells (seven on each side) to total 21 pellets per side.
Each animal was trained for 15 minutes on the Montoya Staircase and returned to its
cage. Training occurred daily for one-and-one-half weeks during the dark cycle to best
accommodate the animals’ nocturnal circadian rhythm (Dauchy et al, 2010). Training
data were collected to determine pre-stroke function. The number of pellets retrieved by
each forepaw was measured, and the highest number recovered was noted as the prestroke function. By the end of training, animals must have been able to retrieve at least
nine pellets with each forepaw to be included in the post-stroke analysis.
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Figure 1.
The Montoya Staircase. (A) This schematic shows the Montoya Staircase, a functional
forelimb reaching and grasping test for rats. The rat is placed inside a Plexiglas box with
access to a raised platform that sits in the middle of a removable double staircase. The
double staircase offers progressive levels of reaching difficulty and allows for the
assessment of individual forelimb function (Montoya et al, 1991). (B) The photograph
shows a rat performing the Montoya Staircase test.
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Figure 1.

(A)

(B)
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Diet Restriction
During training, the animals were placed on a restricted diet to optimize Montoya
Staircase results. To measure the average amount of food eaten ad libitum by the rats, the
food given to the animals the day after their arrival was weighed, and the food remaining
after two days was weighed again. The animals were then fasted overnight and began
Montoya Staircase training the next morning during the dark cycle. Their diet was
restricted to 85% of their normal intake. To monitor their weight loss, the rats were
weighed immediately prior to food restriction as well as every third day until the training
period was complete. If the animals neared their goal weight loss of 15 percent, their
daily food was increased to stabilize their weight. In general, most animals only lost five
to 10 percent of their weight during the training period.

Sucrose Pellets
Sucrose pellets were used to encourage training (Figure 2A). Some of the sucrose
pellets were painted with maple extract. A previous study in our laboratory found that
painting all sucrose pellets with maple extract encouraged the rats to retrieve them
(Figure 2B). However, this study determined that even if only some of the pellets are
painted with maple extract, the rats are still encouraged to retrieve the pellets (Figure 2C).
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Figure 2.
Figures showing data regarding how rats retrieved sucrose pellets painted with different
degrees of maple extract. Thirteen trials were performed on the Montoya Staircase where
pellet retrieval was measured. The x-axis represents the trial number. The y-axis denotes
percentage of pellets retrieved with the animal’s preferred paw, meaning if an animal
retrieved 20 pellets with the left forelimb and 21 pellets with the right forelimb, the right
forelimb is considered the preferred paw and this number was used in our calculations.
Data are presented according to number of pellets retrieved. The minimum number of
pellets an animal had to retrieve with each forelimb to be contained in our study was nine
of the 21 total pellets. Circles represent animals that retrieved 9-11 pellets. Triangles
represent animals that retrieved 12-14 pellets. Squares represent animals that retrieved
15-17 pellets. Diamonds represent animals that retrieved 18-21 pellets. (A) This figure
displays data from a previous study in the laboratory showing the control, where plain
sucrose pellets were used and none were painted with maple extract. (B) This figure
displays data from a previous study in the laboratory showing that animals retrieved more
pellets if all of the sucrose pellets were painted with maple extract. (C) This figure
displays data from our study showing that, even if only some of the sucrose pellets were
painted with maple extract, animals were still encouraged to retrieve a higher number of
pellets compared to the control.
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STROKE INDUCTION
All animals in the study had stroke surgery. Strokes were induced under
anesthesia using two injections of endothelin, a potent vasodilator, into the forelimb
motor cortex of the right hemisphere. All animals had a stroke in the right hemisphere,
which would affect the left forelimb, regardless of handedness or preferred paw
consideration. Coordinates measured from bregma facilitated calculation of the forelimb
motor cortex location.
A list of the substances administered during the course of the stroke induction has been
compiled (Table 1).

Pre-operative Care
The animal was placed in an induction chamber with 5% isoflurane. Once under
anesthesia, the animal was removed from the chamber, and its head was shaved. The
animal was then placed on paper overlying a heating pad and positioned in a stereotactic
device to stabilize its head. A gas mask supplied a constant flow of 2-3% isoflurane
during the procedure. A foot-pinch withdrawal reflex was performed on the animal to
ensure full anesthetization, and Puralube eye ointment was applied to keep the animal’s
eyes moist.
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Table 1.
Table listing substances administered during the course of the stroke induction surgical
procedure.

32

Table 1.
Substance

Concentration

Vehicle Volume

Isoflurane

5%

Oxygen

Inhalation

Isoflurane

2-3%

Oxygen

Inhalation

Puralube
eye
ointment

Topical

Povidoneiodine

Topical

Ethanol

Bupivacaine

Route

Topical

0.25%

Endothelin

400 pmoles/μl

Sterile
saline

Isotonic

Water

Water

0.15 ml

1.5
μl/site

Cortical
injection
(2 mm depth)

2 ml

Subcutaneous
injection
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Notes
Surgical
anesthetic
induction
Surgical
anesthetic
maintenance
Preoperative;
applied to eyes
Preoperative:
once to clean
incision site,
once to scrub
incision site
Postoperative:
once to treat
sutured
incision site
Preoperative;
once to clean
incision site,
performed
between
cleaning and
scrubbing with
povidoneiodine
Analgesic
Injected into
each of two
cortical sites
during surgery
to induce
stroke
Postoperative

Surgical Procedure
The incision site was cleaned with povidone-iodine, cleaned with ethanol, and
then scrubbed with povidone-iodine. A midline incision was made on the animal’s head,
and the edges of the incision were dabbed with bupivacaine. Bregma was then located on
the animal’s skull and marked with a fine-tip marker.
A small burr bit in a microdrill was aligned with bregma. Coordinate
measurements were then used to determine the location of the forelimb motor cortex in
the right hemisphere. The drill was moved anterior-posterior (AP) a distance of 0 mm
and medial-lateral (ML) a distance of -2.5 mm from bregma to drill the first of two holes.
To drill the second hole, the drill was moved AP +1.5 mm and ML -2.5 mm from
bregma. The drill was removed and replaced with a Hamilton syringe containing
endothelin, and 1.5 μl of 400 pmoles/μl endothelin was injected over the course of
several minutes into each site. The injection depth was 2.0 mm.
The incision was closed with resorbable sutures and treated again with
povidone-iodine.

Post-Operative Care
A subcutaneous injection of 2 ml sterile saline was administered before placing
the animal in its cage on a heated pad to recover from anesthesia. The animal was
monitored until awake and moving, at which point it was returned, in its cage, to the
animal rack. When the animal was moving around well, it was given moist chow on the
floor of its cage. The animal was switched back to normal chow by post-stroke day 2.
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POST-STROKE TREATMENT
Treatment after stroke induction involved both a pharmacological component and
a rehabilitation component.

Pharmacological Treatment
Pharmacological treatment was provided in both Experiments 1 and 2. Treatment
began 6-12 hours after stroke induction. Animals received either the vehicle only or the
drug combination fully incorporated into the vehicle.
Because stress can influence neurogenesis among other physiological processes, it
was crucial that stress associated with pharmacological treatment be reduced
(Corbett et al, 2012). The vehicle used in this study was a 3-4 g ball of Pillsbury sugar
cookie dough. This method provided a voluntary oral means for drug delivery and thus
helped decrease stress on the animal (Corbett et al, 2012).
If an animal failed to ingest the cookie dough on three or more occasions, the
animal was removed from the study.
No additional substances were administered to assist with post-operative pain
control or recovery because non-steroidal anti-inflammatory drugs (NSAIDs) and
analgesic opioids can both influence neurogenesis (Goncalves et al, 2010; Hoehn et al,
2005; Sargeant et al, 2008). The infarct analysis aspect in this study depended on the
effects of our drug combination on neurogenesis; therefore, it was imperative that
neurogenesis not be modified by other drugs.
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Treatment: Drug-Treated Rats
The drug combination consisted of 5 mg/kg fluoxetine and 1 mg/kg simvastatin.
The powdered drug combination was fully incorporated into the cookie dough vehicle
and placed in the animals’ cages. Animals received the drug treatment once daily for
90 days following the stroke.

Treatment: Control Rats
Control rats received only the cookie dough vehicle beginning 6-12 hours
post-stroke. They continued receiving the vehicle once daily for 90 days.

Limb Rehabilitation
Limb rehabilitation was provided in Experiment 2 only. The control rats were
divided into two groups: control with rehabilitation and control without rehabilitation
(Table 2). The drug-treated animals were also divided into two groups: drug-treated
with rehabilitation and drug-treated without rehabilitation (Table 2).
Beginning on post-stroke day 8, a rehabilitation shelf containing peanut butter
was hung every other night outside the rehabilitation animals’ cages, and this was
continued for five and one half weeks. The shelves were positioned in such a way so the
animals could only use the contralateral forelimb (stroke-affected limb) to reach the
peanut butter (Figure 3).
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Table 2.
Table displaying how animals were grouped. Experiment 1: drug-treated and control.
Experiment 2: drug-treated with rehabilitation, drug-treated without rehabilitation,
control with rehabilitation, and control without rehabilitation.

37

Table 2.
Experiment 2:
Rats 600‐637

Experiment 1:
Rats 530‐566
Group

FS
Control
Died

Total Animals*

Group

Total Animals

Rehabilitation

No
Rehabilitation

18
18
1

FS
Control
Died

18
17
3

15
14

3
3

*No animals in Experiment 1 received rehabilitation.
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Figure 3.
Pictures of rehabilitation shelves. (A) This series of pictures shows varying degrees of
peanut butter retrieval. Because of the shelf design, it was easy to measure whether an
animal took no peanut butter, some peanut butter, or all of the peanut butter. (B) This
picture shows a rat taking peanut butter while using the rehabilitation shelf.
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Figure 3.
(A)

(B)
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POST-STROKE FUNCTIONAL TESTING
After stroke induction, animals underwent a series of Montoya Staircase testing.
Each set of testing days allowed for calculation of an initial baseline deficit and
ultimately the measurement of functional recovery. Figure 4 displays a timeline of all
events included in this study.

Calculation of Baseline Functional Deficit
The first set of post-stroke Montoya Staircase testing occurred daily on
post-stroke days 3, 4, and 5. The number of pellets retrieved during this initial
post-stroke functional evaluation allowed for the establishment of a baseline functional
deficit. Both contralateral (affected by stroke) and ipsilateral retrieval was measured.
An animal’s best performance during post-stroke days 3, 4, and 5 was divided by
the animal’s best performance from the pre-stroke training days; multiplying this figure
by 100% produced the percentage of pre-stroke function the animal retained; subtracting
this number from 100% produced the baseline percentage of functional deficit resulting
from the stroke. The formulas and sample calculations are presented in Table 4.

Charting Functional Recovery
Additional series of Montoya Staircase testing charted functional recovery over
time. A total of four testing series took place on post-stroke days 3-5, 29-31, 59-61, and
89-91.
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Figure 4.
Timeline showing timing of details of this study. Events included two weeks of prestroke Montoya training, the stroke surgery, Montoya testing to establish baseline
functional deficits at post-stroke days 3-5, and additional Montoya testing periods to
chart functional recovery at post-stroke days 29-31, 59-61, and 89-91. If assigned to a
rehabilitation group, animals received rehabilitation beginning on post-stroke 8 for
five-and-one-half weeks.
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Figure 4.
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After 91 days, the best performance from post-stroke days 89, 90, and 91 can be
divided by the best pre-stroke testing figure to give the final functional ability;
multiplying this number by 100% gives the percent of functional ability; subtracting this
number from 100% gives a final figure for functional deficit. Subtracting the resulting
functional deficit from the original baseline functional deficit gives the percentage of
pre-stroke function recovery.
All functional recovery calculations were performed for both contralateral
(affected by stroke) and ipsilateral forelimbs.

INFARCT ANALYSIS
Euthanization
Animals were injected intraperitoneally with Euthasol (100 mg/kg sodium
pentobarbital). Full anesthetization was confirmed with a foot-pinch withdrawal reflex
test.
The animals were then exsanguinated. An incision was made to expose the heart.
The apex of the heart was gently clamped with a hemostat. The apex was cut with
scissors, and a blunt-edged cannula was inserted through the apex incision into the left
ventricle at a depth deeper than the location of the hemostat. An incision was also made
in the right atrium. The tissue was perfused first with 100 ml of phosphate buffered
solution (PBS) and then fixed using a 4% paraformaldehyde in PBS.
After euthanization, the brain was removed and placed in 4% paraformaldehyde
overnight followed by a 30% sucrose solution for three days.
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Cryostat Sectioning of Brain Tissue
The tissue was set in Optimal Cutting Temperature (OCT) compound and frozen
using a Peltier device on the cryostat. In approximately 30 minutes, equilibrium was
reached between the tissue temperature and the chamber temperature. The frozen tissue
was then placed in the cryostat and sliced at a thickness of 50 μm. Each slice was placed
sequentially into one of four vials containing PBS, and the vials were labeled with the
corresponding rat’s identification number. The infarct analysis vial was used for this
study; the remaining three vials were used for other work studying evidence of
neurogenesis using expression of DCX and MAP 2.

Slide Preparation
In order to analyze the brain tissue, each slice was mounted on gel-subbed glass
slides and stained with Cresyl Violet stain in anticipation of microscope examination.

Tissue Mounting
The vial containing an animal’s brain slices for infarct analysis was dumped into a
Petri dish and filled half-way with additional PBS. A glass slide was labeled with the
corresponding rat’s identification number, placed at an angle in the dish, and wetted with
PBS. Using a small-tip paintbrush, tissue slices were mounted onto the slide. Once the
slide was full, it was set aside to dry.
As the brain slices were mounted, care was taken to ensure the tissue was not
folded or damaged.
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Staining
After the tissue was dry, the slides were placed into slide racks. The tissue was
stained using a Cresyl Violet (Nissl) stain composed of 2.5 g Cresyl Violet, 300 ml water,
30 ml 1 M sodium acetate, and 170 ml 1 M acetic acid. The stain and wash solutions
were poured into a series of staining dishes in a chemical hood. The slices were then
stained using a series of timed washes: Cresyl Violet stain for 15 minutes, distilled water
for 5 minutes, 70% ethanol for 5 minutes, 95% ethanol for 5 minutes, two washes of
100% ethanol for 5 minutes each, and two washes of Xylene for 5 minutes each.
The slides were left in the slide racks in the hood to dry. After the stained tissue
was dry, cover slips were placed over the tissue using DPX, a permanent mordant.

Image Capture Using SPOT Scope
The slides were analyzed using Wright State University’s Microscopy Core
Facility’s Olympus Epi Fluorescence SPOT Scope with RT color camera. Slides were
examined under brightfield using the 4x scan objective lens. SPOT software provided
means to add calibration marks (200 μm) and capture images of the damaged brain tissue
in each brain slice.

Creating Image Montages
In cases where brain slices contained large areas of damage, multiple overlapping
images were captured to record all damage. These images were merged into one large
image using Adobe Photoshop.
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Measuring Infarct Volume
Images were opened using ImageJ software. In ImageJ, the measuring tool was
calibrated and used to measure infarct volume by tracing the area of damage and
recording the listed measurement. This measurement gave infarct volume in mm3.

Infarct Volume Calculations
Because of the fact that every fourth slice (rather than every slice) of tissue was
used for capturing infarct data, calculations were required to determine total infarct
volume for each animal.
First, the infarct area for each individual tissue slice provided by ImageJ was
multiplied by 0.05 because the tissue sections were 50 μm (0.05 mm) thick; multiplying
the area by the 0.05 mm thickness provided the total infarct volume for that slice. The
slice volumes for each rat were then added together, and the sum was multiplied by 4
(because every fourth slice was used) to provide the infarct volume for a single rat.
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III. RESULTS

PRE- AND POST-STROKE ANALYSIS
Data for this study were obtained from two separate experiments. Both
experiments used the same drug combination, dosage, pre-stroke analysis, and
post-stroke analysis.

Pre-Stroke Analysis
All animals received pre-stroke training using the Montoya Staircase daily for
one-and-one-half weeks. Each animal was trained for 15 minutes and returned to its
cage.
By counting the number of pellets retrieved by each animal during training
period, pre-stroke function was established. This was important because it allowed for
calculation of functional deficit and retained pre-stroke function after a stroke was
induced. Animals that did not retrieve at least nine pellets with each forepaw did not
meet training criteria and were therefore not used to obtain functional recovery data.
Pre-stroke Montoya training data were reviewed for animals that would receive
rehabilitation (rehabilitation animals in Experiment 2) and animals that would not receive
rehabilitation (non-rehabilitation animals for Experiment 2 plus all Experiment 1
animals). Figure 5 shows that the mean number of pellets retrieved out of 21 total pellets
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with each forelimb ranged from 16-18 pellets. Even though animals did trend toward
retrieving more pellets with their right forelimb, handedness was not an apparent issue
because the numbers retrieved with each forelimb were very similar. There was a small
significant difference between pre-stroke function of the right and left forelimb for those
animals that eventually underwent post-stroke rehabilitation, but there was no significant
difference in right and left forepaw performance in the animals that would receive no
post-stroke rehabilitation.
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Figure 5.
Figure displaying the performance by right and left forepaws for animals that were
assigned into either the post-stroke rehabilitation group (Experiment 2) or the post-stroke
non-rehabilitation group (Experiments 1 and 2). The maximum number of pellets that
could be retrieved by either forepaw was 21 pellets. The right forepaw retrieved
significantly more pellets in the group that eventually underwent post-stroke
rehabilitation (ANOVA, p= 0.002; Tukey post-hoc test). No significant difference
existed between right and left forepaw retrieval of the animals that did not eventually
receive rehabilitation.
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Figure 5.
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Post-Stroke Analysis
After stroke induction, animals in the drug-treated group received 5 mg/kg
fluoxetine and 1 mg/kg simvastatin via a sugar cookie dough vehicle. Animals in the
control group received the vehicle only. Drug/vehicle administration took place once
daily for 90 days post-stroke.
A Montoya Staircase functional test was performed at post-stroke days 3-5. This
data allowed us to establish a baseline deficit for each animal that met pre-stroke training
criteria. This also allowed us to determine if the animal exhibited a contralateral forelimb
deficit, a bilateral deficit, or no deficit.
Additional Montoya Staircase functional tests were performed at post-stroke days
29-31 (simplified as “post-stroke day 30”), post-stroke days 59-61 (simplified as
“post-stroke day 60”), and post-stroke days 89-91 (simplified as “post-stroke day 90”).
This data allowed us to chart functional recovery.
After euthanization and tissue preparation, the brain tissue was analyzed. Based
on the endothelin injection site, evidence of ipsilateral infarcts (caused by the endothelin
injections), contralateral infarcts, corpus callosum damage, and bilateral infarcts were
reviewed. Infarct volume was also measured.

EXPERIMENT 1
In 2012, Experiment 1 reviewed earlier administration of the defined drug
combination – 5 mg/kg of fluoxetine and 1 mg/kg of simvastatin – with delivery at
6-12 hours post-stroke. No rehabilitation component was involved. The animals were
divided into one of two groups: drug-treated or control.
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Presented Deficits
Both animal groups were reviewed for deficit type. Three control animals
presented less than a 20% deficit after stroke surgery. Animals are considered to have no
deficit if the baseline functional deficit measured less than 20%, and such animals were
not included in the study of functional recovery. In regard to functional deficit, thirteen
animals (nine drug-treated and four control animals) presented bilateral deficits. Bilateral
deficits can be explained by analyzing the brain tissue for the presence of either
contralateral cortical damage in addition to the ipsilateral infarct (caused by the
endothelin injections) or corpus callosum damage. These data are presented in Table 3.
Of the nine drug-treated animals with bilateral deficits, four showed evidence of
contralateral cortical damage in addition to ipsilateral infarcts. Three animals did not
have contralateral cortical damage but did show corpus callosum damage; this corpus
callosum damage could potentially cause the bilateral deficit. The source of the bilateral
deficit could not be determined in two animals: Rat 566 and Rat 544. Rat 566 was used
for a gene expression study, so brain tissue sections were not available for analysis;
therefore, it cannot be determined whether this animal had contralateral or corpus
callosum damage. Rat 544 showed bilateral deficits but did not show contralateral
damage or corpus callosum damage; perhaps the bilateral deficit was due to damage not
visible on the tissue slices we reviewed, since we only analyzed every fourth slice.
Of the four control animals with bilateral deficits, three animals showed evidence
of contralateral cortical damage in addition to ipsilateral infarcts. The one animal that did
not show contralateral cortical damage did demonstrate ipsilateral corpus callosum
damage, which could have caused the bilateral deficit.
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Table 3.
A table showing how animals were grouped in Experiment 1 and the types of deficits
observed. None of the animals in this experiment received rehabilitation.

54

Table 3.
Experiment 1: Rats 530‐566
Group

FS
Control
Died

Total
Animals

18
18
1

Montoya
Criteria Not
Met

No Deficit
(< 20%)

Bilateral
Deficits

Contralateral
Cortical
Damage

Ipsilateral
Corpus
Callosum
Damage

4
4

0
3

9
4

4
3

3
1
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Functional Recovery
Functional deficits and recovery were charted over time. The percent of
pre-stroke function retained was calculated by dividing an animal’s best performance at a
given time (e.g., best performance from post-stroke days 29-31) by the animal’s best
performance from the pre-stroke training days and multiplying that figure by 100%.
Subtracting this value from 100 provided the percent of functional deficit. Percent
functional recovery was calculated by subtracting the function retained at post-stroke
days 3-5 (when the baseline deficit was determined) from the function retained at a given
time (e.g., function retained at post-stroke days 29-31). Sample calculations are
presented in Table 4.

Bilateral Deficits
Seven animals with bilateral deficits displayed evidence of contralateral cortical
damage in addition to the ipsilateral infarcts (caused by the endothelin injections).
Contralateral recovery and total recovery of these animals over time was analyzed
(Table 5).
Four animals with bilateral deficits had corpus callosum damage in addition to the
ipsilateral infarcts. Contralateral recovery and total recovery of these animals over time
was analyzed as well (Table 6).
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Total Recovery
Total recovery was charted over time and involved measuring contralateral
recovery (recovery of the stroke-affected limb) together with ipsilateral recovery
(Figure 6). While recovery at post-stroke days 30 and 60 was not statistically different
between groups, total recovery at post-stroke day 90 was statistically higher for
drug-treated animals over controls.
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Table 4.
Tables showing sample calculations of baseline functional deficit at post-stroke days 3-5
and functional deficit/recovery at post-stroke days 29-31, 59-61, and 89-91. This sample
used data for Rat 605 from the drug-treated with rehabilitation group in Experiment 2.

Baseline functional deficit was calculated as follows:
post-stroke # pellets / pre-stroke # pellets = baseline function retained
(1 – baseline function retained) x 100 = % baseline functional deficit

Functional Deficit and Functional Recovery were calculated as follows (calculations
were performed for PSD 60 and 90 as well; calculations were also performed for
both contralateral and ipsilateral data):
PSD30 # pellets / pre-stroke # pellets = PSD 30 function retained
(1 – PSD30 function retained) x 100 = % deficit
(PSD 30 function retained – baseline function retained) x 100 = % recovery
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Table 4.
Rat 605, Pre-stroke Function
Best
Performance
Pre-stroke
20 L, 21 R

Rat 605, Baseline Functional Deficit
Best
Performance
PSD 3, 4, 5
11 L, 20 R

Contralateral Ipsilateral
Deficit
Deficit
0.45
(45% deficit)

0.05
(5% deficit)

Rat 605, Deficit/Recovery at 30 Days Post-Stroke
Best
Contralateral
Performance
Deficit
PSD 29, 30, 31
13.5 L, 20.5 R 0.33
(33% deficit)

Ipsilateral
Deficit

Contralateral
Recovery

Ispilateral
Recovery

0.02
(2% deficit)

0.13
(13% recovery)

0.02
(2% recovery)

Ipsilateral
Deficit

Contralateral
Recovery

Ispilateral
Recovery

0.095
(9.5% deficit)

0.20
(20% recovery)

-0.05
(-5% recovery)

Ipsilateral
Deficit

Contralateral
Recovery

Ispilateral
Recovery

0.048
(4.8% deficit)

0.30
(30% recovery)

0.00
(0% recovery)

Rat 605, Deficit/Recovery at 60 Days Post-Stroke
Best
Contralateral
Performance
Deficit
PSD 59, 60, 61
15 L, 19 R
0.25
(25% deficit)

Rat 605, Deficit/Recovery at 90 Days Post-Stroke
Best
Contralateral
Performance
Deficit
PSD 89, 90, 91
17 L, 20 R
0.15
(15% deficit)
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Table 5.
Review of contralateral recovery (recovery of the stroke-affected limb) and total recovery
for animals that functionally presented bilateral deficits, specifically those animals with
contralateral cortical damage in addition to the ipsilateral infarcts. Values for
contralateral recovery and total recovery over time from post-stroke days 29-31, 59-61,
and 89-91 are displayed.
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Table 5.

Experiment
1

PSD 29‐31

PSD 59‐61

PSD 89‐91

Contralateral
Recovery

Total
Recovery

Contralateral
Recovery

Total
Recovery

Contralateral
Recovery

Total
Recovery

FS (N=4)*

29.02%

55.66%

33.68%

70.93%

34.71%

73.00%

C (N=3)**

31.22%

52.24%

22.22%

45.74%

18.52%

50.60%

Group

*FS rats: 540, 542, 546, 553
**Control rats: 539, 547, 562

61

Table 6.
Review of contralateral recovery (recovery of the stroke-affected limb) and total recovery
for animals that functionally presented bilateral deficits, specifically those animals with
corpus callosum damage (not contralateral cortical damage) in addition to the ipsilateral
infarcts. Values for contralateral recovery and total recovery over time from post-stroke
days 29-31, 59-61, and 89-91 are displayed.
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Table 6.

Experiment
1

PSD 29‐31

PSD 59‐61

PSD 89‐91

Contralateral
Recovery

Total
Recovery

Contralateral
Recovery

Total
Recovery

Contralateral
Recovery

Total
Recovery

FS (N=3)*

1.76%

26.06%

22.31%

46.79%

20.74%

57.76%

C (N=1)**

47.06%

62.85%

44.12%

67.80%

50.00%

73.68%

Group

*FS rats: 549, 557, 563
**Control rats: 545
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Figure 6.
Comparison of total recovery (ipsilateral and contralateral combined) in control animals
versus drug-treated animals at post-stroke days 30, 60, and 90. The x-axis shows time at
post-stroke days 30, 60, and 90 for the control animals in yellow on the left and the
drug-treated animals in green on the right. The y-axis denotes total recovery; multiplying
the y-axis values by 100% gives the total recovery in a percentage. While no significant
difference is shown at post-stroke days 30 or 60, there is a significant difference (T test,
p=0.022) between the recovery of drug-treated animals and control animals at post-stroke
day 90.
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Figure 6.
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Infarct Volume
In contrast to the previous study in our laboratory where drugs were administered
at 20-26 hours post-stroke, larger infarcts were presented in this study (6-12 hour
post-stroke delivery). Control animals, showed similar infarct sizes to those in the
previous study. However, the drug-treated animals had much larger infarcts than
previously observed.
The previous study in our laboratory with drug administration at 20-26 hours
post-stroke also exhibited functional recovery along with smaller infarct sizes; there
appeared to be a correlation between the two factors. Yet, a correlation did not appear to
be evident in this study (6-12 hour post-stroke delivery).
A comparison of infarct size to contralateral functional recovery is presented in
Figure 7. The best recovery was observed in animals with the smallest infarcts around
8 mm3. A trend was observed between animals with recovery less than 20% and animals
with recovery greater than 20%, as more drug-treated animals had recovery above 20%
while more control animals had recovery below 20%. In addition, at smaller infarct
sizes, there was not much separation between recovery in drug-treated animals and
recovery in control animals. However, at larger infarct sizes, more separation between
recovery in drug-treated animals and recovery in control animals is observed.
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Figure 7.
Figure plotting individual animal data comparing infarct volume to contralateral
functional recovery (recovery of stroke-affected limb) in animals from Experiment 1.
Limb rehabilitation was not a factor in this experiment. The yellow circles represent the
10 control animals. The green triangles represent the 12 drug-treated animals. The xaxis denotes infarct volume in mm3 (measured at the end of the study). The y-axis shows
percent contralateral recovery seen after 90 days. The horizontal line is placed at 20%
contralateral recovery for reference. The vertical line is placed at 8 mm3 infarct size for
reference. A trend (Fisher’s Exact Test, p=0.23) was present between drug-treated and
control animals with recovery less than 20% and drug-treated and control animals with
recovery greater than 20%. The drug-treated animals appeared to show a higher
percentage of animals with recovery greater than 20%. In order to achieve sufficient
power for this statistical set, the sample size for each group would need to be doubled at
the very least.
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Figure 7.
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EXPERIMENT 2
In 2013, Experiment 2 reviewed earlier administration of the defined drug
combination – 5 mg/kg of fluoxetine and 1 mg/kg of simvastatin – with delivery at
6-12 hours post-stroke; this is the same as Experiment 1. However, in Experiment 2, a
rehabilitation component was added. The animals were divided into one of four groups:
drug-treated with rehabilitation, drug-treated without rehabilitation, control with
rehabilitation, or control without rehabilitation.

Presented Deficits
All animal groups were reviewed for deficit type. Seven animals (two drugtreated animals with rehabilitation and five control animals with rehabilitation) presented
less than a 20% deficit after stroke surgery. Animals are considered to have no deficit if
the baseline functional deficit measured less than 20%, and such animals were not
included in the study of functional recovery. Four animals (one drug-treated animal with
rehabilitation, two control animals with rehabilitation, and one control animal without
rehabilitation) presented bilateral deficits when analyzing their post-stroke functional
deficit. Bilateral deficits can be explained by the presence of contralateral cortical
damage in addition to the ipsilateral infarct (caused by the endothelin injections). No
animals in Experiment 2 displayed corpus callosum damage as a sole explanation for
bilateral deficits. These data are presented in Table 7.
The one drug-treated animal with a bilateral deficit received rehabilitation and
showed evidence of contralateral cortical damage in addition to ipsilateral infarcts; the
contralateral damage explains the bilateral deficit.
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Of the three control animals with bilateral deficits, two received rehabilitation and
showed evidence of contralateral cortical damage in addition to ipsilateral infarcts; this
contralateral damage explains the bilateral deficits. The third control animal with
bilateral deficits did not receive rehabilitation. This animal (Rat 617) was used for a gene
expression study, so brain tissue sections were not available for analysis. Therefore, it
cannot be determined whether this animal had contralateral cortical damage.
Contralateral and ipsilateral deficits across the four groups were examined. These
data are presented in Figure 8. Contralateral deficit (deficit in stroke-affected limb)
seemed to increase across groups, with rehabilitation groups showing less deficit than
non-rehabilitation groups, regardless of whether they were control or drug-treated
animals. The control animals with rehabilitation showed the lowest contralateral deficits.
The drug-treated animals with rehabilitation had larger contralateral deficits. The control
animals without rehabilitation had larger contralateral deficits still. Finally, the largest
contralateral deficits were seen in the drug-treated animals without rehabilitation.
Ipsilaterally, the control animals with rehabilitation showed the smallest deficits. The
drug-treated animals without rehabilitation had larger ipsilateral deficits, followed only
with a slight increase by drug-treated animals with rehabilitation. Finally, the largest
ipsilateral deficits were seen in the control animal without rehabilitation.
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Table 7.
A table showing how animals were grouped in Experiment 2 and the types of deficits
observed.
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Table 7.

Experiment 2: Rats 600‐637
Group

Total
Animals

FS
Control
Died

18
17
3

Rehab.

No
Rehab.

Montoya
Criteria Not
Met

No Deficit
(< 20%)

Bilateral
Deficits

Contralateral
Cortical
Damage

15
14

3
3

2R
1 NR

2R
5R

1R
2R, 1NR

1R
2R

R=Animal received rehabilitation
NR=Animal received no rehabilitation
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Figure 8.
Comparison of functional deficits at the end of the study in control with rehabilitation
(hashed yellow), control without rehabilitation (solid yellow), drug-treated with
rehabilitation (hashed green), and drug-treated without rehabilitation (solid green).
Contralateral (stroke-affected limb) and ipsilateral deficits were plotted separately. The
x-axis distinguishes the contralateral deficits as compared to the ipsilateral deficits. The
y-axis shows functional deficit; multiplying the y-axis values by 100% gives the
functional deficit in a percentage. The control group without rehabilitation had a sample
size of 2, so the bars on this group are standard deviation bars, while the bars on all other
groups are standard error bars. Due to the low sample sizes of the control and drugtreated animal groups without rehabilitation, statistics were not run.
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Figure 8.
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Functional Recovery
Functional deficits and recovery were charted over time. The percent of
pre-stroke function retained was calculated by dividing an animal’s best performance at a
given time (e.g., best performance from post-stroke days 29-31) by the animal’s best
performance from the pre-stroke training days and multiplying that figure by 100%.
Subtracting this value from 100 provided the percent of functional deficit. Percent
functional recovery was calculated by subtracting the function retained at post-stroke
days 3-5 (when the baseline deficit was determined) from the function retained at a given
time (e.g., function retained at post-stroke days 29-31).

Contralateral Recovery
Contralateral recovery (recovery of the stroke-affected limb) of the control and
drug-treated animals was reviewed over time at post-stroke days 30, 60, and 90. Data
were analyzed separately with rehabilitation animals and non-rehabilitation animals.
For the rehabilitation animals (Figure 9), no significant differences existed in
contralateral recovery between drug-treated and control animals at any point in time.
Because no significant difference existed, it could be stated that drug treatment does not
appear to add any benefit when rehabilitation is received because recovery is similar
between drug-treated and control groups across all time points. However, one notable
observation was that drug-treated animals at post-stroke day 30 showed recovery above
30% while control animals showed recovery below 20%; this suggests it is possible that
adding drug treatment to rehabilitation facilitates a quicker initial increase in recovery
early on.
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For the non-rehabilitation animals (Figure 10), control animals appeared to show
higher contralateral recovery at post-stroke day 30 over drug-treated animals. However,
recovery appeared to drop dramatically in control animals at post-stroke days 60 and 90
while the drug-treated animals showed increases in contralateral recovery consistently
over time. Drug-treated animals appeared to show higher contralateral recovery in the
end. Both control and drug-treated animals displayed functional recovery around 20% at
30 days post-stroke. However, while control animals lost recovery over time and end the
study with recovery around 10%, drug treatment allowed the animals to gain recovery
over time and end the study with recovery around 30%, thus better maintaining the initial
recovery. It could be stated that trends are evident as described above, but despite these
observations, the sample size of non-rehabilitated animals in Experiment 2 was extremely
small. To best analyze data pertaining to non-rehabilitated animals, Figure 13 should be
referenced because it combines all non-rehabilitation animal data from Experiments 1
and 2, resulting in a larger sample size, and does in fact present significant differences.
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Figure 9.
Figure comparing contralateral recovery (recovery of stroke-affected limb) over time
between control animals that received rehabilitation and drug-treated animals that
received rehabilitation. The x-axis denotes time, reviewing post-stroke days 30, 60, and
90 for control animals on the left in yellow and drug-treated animals on the right in green.
The y-axis exhibits contralateral recovery; multiplying the y-axis value by 100% gives
the contralateral recovery in a percentage.
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Figure 9.
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Figure 10.
Figure comparing contralateral recovery (recovery of stroke-affected limb) over time
between control animals that did not receive rehabilitation and drug-treated animals that
did not receive rehabilitation. The x-axis denotes time, reviewing post-stroke days 30,
60, and 90 for control animals on the left in yellow and drug-treated animals on the right
in green. The y-axis exhibits contralateral recovery; multiplying the y-axis value by
100% gives the contralateral recovery in a percentage. It is important to note only
6 animals composed the sample size for this figure (3 drug-treated animals and 2 control
animals).
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Figure 10.
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Infarct Volume
Like Experiment 1, larger infarcts were presented with Experiment 2 when
compared to our previous study with drug administration at 20-26 hours post-stroke, and
a correlation between infarct size and functional recovery was not observed.
A comparison between infarct size and contralateral functional recovery is
presented in Figure 11 for all animals in Experiment 2 that received rehabilitation. The
best recovery appeared to be observed in animals with larger infarcts greater than 8 mm3
in size. No significant difference was observed between the control and drug-treated
groups with recovery greater than 20%. The majority of drug-treated animals with
rehabilitation had recovery above 20%; the majority of the control animals with
rehabilitation also had recovery above 20%. In addition, at smaller infarct sizes, there
was not much separation between recovery in drug-treated animals and recovery in
control animals. However, at larger infarct sizes, more separation between recovery in
drug-treated animals and recovery in control animals was detected.
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Figure 11.
Figure plotting individual animal data comparing infarct volume to contralateral
functional recovery (recovery of stroke-affected limb) in animals from Experiment 2,
which involved a limb rehabilitation component. The yellow circles represent six control
animals that received rehabilitation. The green circles represent eight drug-treated
animals that received rehabilitation. Animals that did not receive rehabilitation are not
represented in this figure. The x-axis denotes infarct volume in mm3 (measured at the
end of the study). The y-axis shows percent contralateral recovery seen after 90 days.
The horizontal line is placed at 20% contralateral recovery for reference. The vertical
line is placed at 8 mm3 infarct size for reference. No significant difference (Fisher’s
Exact Test) was present between the control and drug-treated groups with recovery
greater than 20%.
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Figure 11.
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COMBINED DATA
Data from Experiments 1 and 2 were combined to analyze the full scope of early
drug administration at 6-12 hours post-stroke. All animals from Experiment 1 (no
rehabilitation) were grouped with the non-rehabilitation animals from Experiment 2.

Presented Deficits
Contralateral (in stroke-affected limb) and ipsilateral deficits across the combined
groups from Experiments 1 and 2 were reviewed: control animals with rehabilitation,
drug-treated animals with rehabilitation, control animals without rehabilitation, and
drug-treated animals without rehabilitation. These data are presented in Figure 12.
Functional deficit seemed to increase across groups, with rehabilitation groups showing
less deficit than non-rehabilitation groups, regardless of whether they were control or
drug-treated animals. The control animals with rehabilitation showed the lowest
functional deficits, both contralateral and ipsilateral. The drug-treated animals with
rehabilitation had larger deficits, both contralateral and ipsilateral. The control animals
without rehabilitation had larger deficits still, both contralateral and ipsilateral. Finally,
the largest deficits were seen in the drug-treated animals without rehabilitation, both
contralateral and ipsilateral. Additionally, while the drug-treated animals without
rehabilitation showed larger deficits than the control animals without rehabilitation, the
difference was very small when looking at contralateral deficits between the two groups.
Statistical analysis showed the ipsilateral deficits were significantly smaller than the
contralateral deficits. However, there was no significant difference between any
drug-treated group when compared to its corresponding control group.
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Figure 12.
Comparison of functional deficits at the end of the study in all animals from Experiments
1 and 2 combined: control with rehabilitation (hashed yellow), control without
rehabilitation (solid yellow), drug-treated with rehabilitation (hashed green), and
drug-treated without rehabilitation (solid green). Contralateral (stroke-affected limb) and
ipsilateral deficits were plotted separately. The x-axis distinguishes the contralateral
deficits as compared to the ipsilateral deficits. The y-axis shows functional deficit;
multiplying the y-axis values by 100% gives the functional deficit in a percentage.
Statistical analysis showed the ipsilateral deficits are significantly different from the
contralateral deficits. However, there is no significant difference between any
drug-treated group when compared to its corresponding control group. This figure is
similar to the data shown in Figure 8; however, Figure 12 represents Experiment 1 data
added to the Experiment 2 data from Figure 8.
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Figure 12.
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Functional Recovery
Functional deficits and recovery were charted over time. The percent of
pre-stroke function retained was calculated by dividing an animal’s best performance at a
given time (e.g., best performance from post-stroke days 29-31) by the animal’s best
performance from the pre-stroke training days and multiplying that figure by 100%.
Subtracting this value from 100 provided the percent of functional deficit. Percent
functional recovery was calculated by subtracting the function retained at post-stroke
days 3-5 (when the baseline deficit was determined) from the function retained at a given
time (e.g., function retained at post-stroke days 29-31).

Contralateral Recovery
Contralateral recovery (recovery of stroke-affected limb) of all non-rehabilitation
control and drug-treated animals from Experiments 1 and 2 combined was reviewed over
time at post-stroke days 30, 60, and 90 (Figure 13).
A significant difference existed between drug-treated animals at post-stroke days
30 and 90, showing recovery improved significantly over time with drug treatment.
There was a significant difference between the control animals at post-stroke days 30 and
90 as well, showing recovery decreased significantly over time without drug treatment.
Finally, there was a significant difference between drug-treated animals and control
animals at post-stroke day 90, which demonstrates drug-treated animals recovered
significantly better than the controls.
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Figure 13.
Figure comparing contralateral recovery (recovery of stroke-affected limb) over time
between all non-rehabilitation control and drug-treated animals from Experiments 1 and 2
combined. The x-axis denotes time, reviewing post-stroke days 30, 60, and 90 for control
animals on the left in yellow and drug-treated animals on the right in green. The y-axis
exhibits contralateral recovery; multiplying the y-axis value by 100% gives the
contralateral recovery in a percentage. A significant difference exists between drugtreated animals at post-stroke days 30 and 90. A significant difference also exists
between the control animals at post-stroke days 30 and 90. Lastly, a significant
difference (Two-Way Repeated Measures ANOVA, Holm-Sidak post-hoc, p=0.047)
exists between drug-treated animals and control animals at post-stroke day 90.
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Figure 13.
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Contralateral recovery (recovery in stroke-affected limb) at the end of the study
from Experiments 1 and 2 was reviewed. The data are presented in Figure 14. No
significant difference was seen in the drug-treated animals between those that received
rehabilitation and those that did not; recovery was virtually the same. The control
animals appeared to show more functional recovery if they had rehabilitation, but no
significant difference was seen between control animals that received rehabilitation and
those that did not. No significant difference was seen between control animals with
rehabilitation and drug-treated animals with rehabilitation, although drug-treated animals
with rehabilitation appeared to show slightly higher recovery than the controls with
rehabilitation. One significant difference did present, though, showing drug-treated
groups (both rehabilitation and no rehabilitation) produced significantly higher recovery
than the control group without rehabilitation.
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Figure 14.
Figure showing the effects of rehabilitation on contralateral recovery (recovery of
stroke-affected limb) at the end of the study across Experiments 1 and 2. The four groups
reviewed are control with rehabilitation (hashed yellow), control without rehabilitation
(solid yellow), drug-treated with rehabilitation (hashed green), and drug-treated without
rehabilitation (solid green). The x-axis denotes the control groups as compared to the
drug-treated groups. The y-axis shows contralateral functional recovery as a decimal;
multiplying this number by 100% provides the percentage of contralateral functional
recovery. A significant difference is observed for Factor A (control versus drug) in the
ANOVA. Tukey Post Hoc analysis showed a statistical difference between both
drug-treated groups (rehabilitation and no rehabilitation) and control animals in the no
rehabilitation group. No significant difference exists between the control animals with
rehabilitation and the control animals without rehabilitation. There was, however, a
trend, which would need increased sample sizes to resolve. No significant difference
exists between the control animals with rehabilitation and the drug-treated animals with
rehabilitation.
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Figure 14.
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Infarct Volume
While our laboratory believed drug-treated animals would exhibit smaller infarct
sizes than controls, this was not observed in this study. Figure 7 compared infarct size to
contralateral functional recovery with Experiment 1 (no rehabilitation); Figure 11
compared infarct size to contralateral functional recovery with all rehabilitated animals in
Experiment 2. Figure 15 compares Figure 7 (Figure 15A) to Figure 11 (Figure 15B).
In Figure 15A (no rehabilitation), the best recovery developed in animals with
smaller infarcts around 8 mm3. No significant difference was presented between drugtreated/control animals with recovery less than 20% and animals with recovery greater
than 20%, although a trend was observed toward drug-treated animals having greater
recovery.
While Figure 15A showed smaller infarcts produced better recovery in
non-rehabilitated animals, Figure 15B reviewed only rehabilitated animals and shows the
best recovery with larger infarcts greater than 8 mm3. No significant difference was
presented in Figure 15B between drug-treated/control animals with recovery less than
20% and animals with recovery greater than 20%, and in contrast to Figure 15A, a trend
was not observed, suggesting drug-treated animals did not have greater recovery over
controls.
Animals in the right upper quadrant of the figures (infarcts larger than 8 mm3,
recovery greater than 20%) were compared to animals elsewhere in the figures. When
the data from Figure 15A data (no rehabilitation) was compared to the data from
Figure 15B (rehabilitation), a statistical difference was shown, implying control animals
recover better if they receive rehabilitation. Without rehabilitation, no control animals
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showed recovery above 20% unless their infarct size was smaller than 8 mm3. However,
with rehabilitation, recovery was seen above 20%, even with larger infarcts.
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Figure 15.
Comparison of infarct volume to contralateral functional recovery (of stroke-affected
limb) between Experiments 1 and 2. The x-axes denote infarct volume (at end of study)
in mm3, and the y-axes show percent contralateral recovery after 90 days. The horizontal
lines at 20% recovery and the vertical lines at 8 mm3 infarct size are for reference.
(A) Infarct volume and contralateral recovery from Experiment 1, where limb
rehabilitation was not involved, are compared. The yellow circles represent 10 control
animals. The green triangles represent 12 drug-treated animals. No significant difference
existed between drug-treated and control animals with recovery less than 20% and
animals with recovery greater than 20%; however, a trend (Fisher’s Exact Test, p=0.23)
was evident, suggesting a 77% chance that drug-treated animals would show better
recovery if sample sizes were larger.
(B) Infarct volume and contralateral recovery from Experiment 2 animals that received
rehabilitation are compared. The yellow circles represent six control animals that
received rehabilitation. The green circles represent the eight drug-treated animals that
received rehabilitation. Animals that did not receive rehabilitation are not represented.
No significant difference was presented between drug-treated and control animals with
recovery less than 20% and animals with recovery greater than 20%.
A Fisher’s Exact Test was run to compare the two figures. Animals in the right upper
quadrant (infarcts larger than 8 mm3, recovery greater than 20%) were compared to
animals falling elsewhere in the figures. A statistical difference existed between these
data from Figure 15A compared to these data from Figure 15B (p=0.008), suggesting that
control animals recovered better, even with larger infarcts, if they received rehabilitation.
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Figure 15.
(A) Experiment 1 (No Rehabilitation)

(B) Experiment 2 (All Rehabilitated Animals)
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IV. DISCUSSION

RESULTS SUMMARY
The results of this thesis present three main discoveries. Variability in functional
recovery with drug treatment and limb rehabilitation as factors was observed. A lack of
correlation between functional recovery and infarct size was also perceived. Lastly,
larger (and sometimes bilateral) infarcts were observed in this study (6-12 hours
post-stroke drug delivery) when compared with previous studies from our laboratory
(20-26 hours post-stroke drug delivery), which may directly relate to our earlier drug
administration.

Effects of Drug Combination and Limb Rehabilitation on Functional Recovery
The observations pertaining to functional recovery when considering drug
treatment and limb rehabilitation are discussed below.

Functional Recovery: Without Rehabilitation
Without rehabilitation where drug treatment was the only variable, the
drug-treated animals showed significantly higher contralateral functional recovery (of
stroke-affected limb) over the control animals. Control animals showed a significant
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decrease in recovery from post-stroke day 30 to post-stroke day 90 (Figure 13).
Conversely, drug-treated animals showed a significant increase in recovery from
post-stroke day 30 to post-stroke day 90 (Figure 13). Total recovery at post-stroke days
30 and 60 was not much different between the control and drug-treated animals, but total
recovery at post-stroke day 90 was significantly higher in the drug-treated animals
(Figure 6, Figure 13). Because the goal of the stroke surgery was to heavily impair the
forelimb motor cortex rather than simply damage it, it took the full course of the study to
see improvement in recovery. The data showed that, in the absence of rehabilitation,
drug-treatment does in fact provide for increased functional recovery compared to the
control. The control animals actually displayed a decrease in recovery and an increase in
deficit over time. This finding is important because some patients may not be able to
perform physical therapy due to other health problems or restrictions; if drug treatment
alone is an option, such patients could obtain a level of increased recovery without
having to take part in rehabilitation.

Functional Recovery: With Rehabilitation
With voluntary rehabilitation, no statistical difference was presented between
recovery in the drug-treated animals and the control animals (Figure 9). The control
animals appeared to recover just as well as drug-treated animals in the presence of
rehabilitation. This suggests that rehabilitation in-and-of itself may present an
opportunity for recovery, which is an important consideration for patients who may have
access to rehabilitation but cannot afford medication or may not be able to take certain
medications.
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Though drug treatment may not add any benefit when rehabilitation is received, it
is possible that drug treatment allows for a quicker initial recovery when rehabilitation is
involved. Recovery over time was about equal between drug-treated and control animals
with rehabilitation, but the drug-treated animals appeared to show faster improvement
initially at post-stroke day 30 over the controls (Figure 9); this suggests that drug
treatment in combination with rehabilitation could possibly be beneficial for patients by
improving functional recovery sooner after stroke.

Functional Recovery: Comparison of All Experimental Groups
Contralateral recovery across the four groups (control with rehabilitation, control
without rehabilitation, drug-treated with rehabilitation, drug-treated without
rehabilitation) (Figure 14) showed the drug-treated groups (both rehabilitation and no
rehabilitation) produced significantly higher recovery than the control group without
rehabilitation. This confirms that without rehabilitation, drug treatment provides for
better recovery. There was no significant difference between drug-treated animals that
received rehabilitation and those that did not, suggesting rehabilitation does not add
anything to the drug treatment. No difference was noted between drug-treated animals
with rehabilitation and control animals with rehabilitation; this implies that rehabilitation
alone may be effective as well.
No difference presented between control animals that received rehabilitation and
those that did not, but there did appear to be a trend insinuating that control animals show
more functional recovery if they have rehabilitation. A statistical difference was
observed when animals with larger infarcts (greater than 8 mm3) and recovery above 20%
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were compared to the remaining animals in Experiments 1 and 2 (Figure 15), implying
control animals recovered better, even with larger infarcts, if they received rehabilitation.
Without rehabilitation, no control animals showed recovery above 20% unless their
infarct size is smaller than 8 mm3. This suggests rehabilitation may be a promising
avenue for stroke patients presenting larger infarcts, such as those who have experienced
hemorrhagic stroke.
Many possible implications for stroke treatment in humans have surfaced
regarding the effects of drug treatment or rehabilitation on recovery. This study proposes
drug treatment alone, rehabilitation alone, and a combination of both could be beneficial
in different cases. It is important to perform additional research in these areas.

Functional Recovery: Gray Matter versus White Matter Recovery
Differences were not observed in functional recovery of gray matter (cortical
damage) versus white matter (corpus callosum damage) in the few cases that showed
bilateral deficits. Recovery was typically noted on both contralateral (stroke-affected
limb) and ipsilateral sides with the drug treatment.

Lack of Correlation Between Infarct Size and Functional Recovery
In contrast to the previous study with drug delivery at 20-26 hours post-stroke,
functional recovery did not seem to correlate well with infarct size in this study. Several
reasons could explain this lack of connection. A large infarct could be detected with very
little consequence to the animal’s function if the infarct encompassed a large
somatosensory area rather than a large motor area. Conversely, a small infarct could be
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detected but with great detriment to the animal’s function if the infarct encompassed a
small but important motor area. This heterogeneity in damage raises questions about how
to classify and analyze damage as well as how to best compare the damage with the
animal’s recovery.
Figure 15 can be referenced for data associated with the issue of heterogeneity in
damage. It is possible that a large infarct could have little effect on an animal’s motor
function if the damage involved mostly the somatosensory area; on the other hand, a
small infarct impairing a sensitive portion of the forelimb motor cortex could greatly
decrease the animal’s motor function despite the small size of the infarct. In Figure 15A,
the two yellow circles representing control animals seen in the lower left of the figure
show very small infarct volumes but largely negative recovery values; it is possible these
animals had severe damage, though small foci, in the forelimb motor cortex.
Without rehabilitation, drug-treated animals and control animals showed more
separation in recovery with larger infarcts, while the recovery between the two groups
was similar if the infarcts were smaller (Figure 15A). The question has been raised
regarding the effectiveness of fluoxetine at different levels of severity, with one study
suggesting fluoxetine only works if the level of damage is severe (Kirsch, 2008).
However, another study suggests it is not that severely depressed patients respond better
to the drug but that they respond less to the placebo (Kirsch et al, 2008). Again, further
investigation is necessary.
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Measuring Off of Bregma
To locate the two endothelin injection sites for stroke induction, coordinates were
measured off of bregma to take out the forelimb motor cortex. An additional
consideration regarding the issue of broader damage is whether measuring off of bregma
is reliable. If the injection site was misplaced, it is possible that a different area of the
cortex was damaged.

Possible Explanations of Larger Infarcts
Larger infarcts were seen in this study with drug administration at 6-12 hours
post-stroke when compared to our laboratory’s previous study with drug administration at
20-26 hours post-stroke. The data are shown in Figure 16. Both the control and
drug-treated groups from Experiment 1 (6-12 hour post-stroke delivery) appeared to
exhibit larger infarct volumes than those from the previous study (20-26 hour post-stroke
delivery), with a significant difference present between the two drug-treated groups.
Additionally, the previous study (20-26 hour post-stroke delivery) showed smaller infarct
volumes in the drug-treated animals over the controls. Conversely, Experiment 1 of this
study (6-12 hour post-stroke delivery) showed larger infarct volumes in the drug-treated
animals over the controls.
While larger infarcts are of course undesirable, drug-treated animals with
rehabilitation showed more functional recovery even with larger infarcts (Figure 15B).
Future studies on this observation could potentially be important with recovery in
hemorrhagic stroke patients, which exhibit larger infarcts.
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Endothelin Injection Issue
One possible explanation for larger infarcts seen in this study is an issue with the
endothelin injection. If some of the endothelin came back up out of the injection hole
and spread across the surface of the cortex, less than the normal amount of endothelin
would have entered the injection site. The endothelin that spread across the cortex could
have constricted surface arteries beyond the targeted injection site, resulting in larger
damage. This could have been caused by differences in the speed of injection.

Secondary Hemorrhagic Stroke
Another possible explanation of larger infarct sizes seen with the drug-treated
animals is the occurrence of a secondary hemorrhagic stroke. Several different infarct
configurations were observed in this study. Figures 17-20 show examples of each and
explain the different configurations of damage.
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Figure 16.
Figure comparing infarct volumes from Experiment 1 from this study (with drug
administration at 6-12 hours post-stroke) to infarct volumes from our laboratory’s
previous study (with drug administration at 20-26 hours post-stroke). The solid yellow
represents control animals from this study; the diagonally-hashed yellow represents
control animals from the previous study. The solid green represents drug-treated animals
from this study; the diagonally-hashed green represents drug-treated animals from the
previous study. The x-axis denotes control groups compared to drug-treated groups. The
y-axis shows infarct volume measured in mm3. A significant difference is present
between the two drug-treated groups. A significant difference (p=0.016) is apparent
between the infarct sizes of drug-treated animals from this study (delivery at 6-12 hours
post-stroke) and drug-treated animals from the previous study (delivery at 20-26 hours
post-stroke).
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Figure 16.
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Figure 17.
Sample infarct showing a simple infarct, easily identifiable at the injection site. Both a
cartoon diagram and an actual image of an example of this type of infarct are shown.
Cartoon outlines of the brain slice are provided for reference. The infarct is outlined in
red and labeled. The corpus callosum and edges of the brain slice are outlined in blue for
reference.
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Figure 17.
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Figure 18.
Sample infarct showing a simple infarct, easily identifiable at the injection site, with
damage that crosses the midline. This additional damage could represent original
damage caused by the initial infarct or evidence of a secondary hemorrhagic stroke. Both
a cartoon diagram and an actual image of an example of this type of infarct are shown.
Cartoon outlines of the brain slice are provided for reference. The infarct is outlined in
red and labeled. The corpus callosum and edges of the brain slice are outlined in blue for
reference.
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Figure 18.
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Figure 19.
Sample infarct showing a simple infarct, easily identifiable at the injection site, with
obvious secondary hemorrhagic stroke damage contralateral to the initial infarct. Both a
cartoon diagram and an actual image of an example of this type of infarct are shown.
Cartoon outlines of the brain slice are provided for reference. The infarct and secondary
hemorrhagic stroke damage are outlined in red and labeled. The corpus callosum and
edges of the brain slice are outlined in blue for reference.
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Figure 19.
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Figure 20.
Sample infarct showing a simple infarct, easily identifiable at the injection site, with
obvious secondary hemorrhagic stroke damage both ipsilateral and contralateral to the
initial infarct. Both a cartoon diagram and an actual image of an example of this type of
infarct are shown. Cartoon outlines of the brain slice are provided for reference. The
infarct and secondary hemorrhagic stroke damage are outlined in red and labeled. The
corpus callosum is outlined in blue for reference.
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Figure 20.
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An initial thought regarding the cause of the observed secondary hemorrhagic
strokes was the possibility of endogenous tPA production. This thought surfaced because
statins provide protection against ischemic injury by upregulating endogenous tPA
(Asahi et al, 2005). However, this does not appear to be the best theory because
25 million people currently take a statin (Associated Press, 2014), and there is no
evidence that anyone taking a statin stops taking it when they have a stroke. In fact, one
study showed people taking statin did worse if the statins were stopped once the stroke
occurred (Blanco et al, 2007). Additionally, the dose of simvastatin administered to rats
in our study is extremely small when compared to the scope of human doses
(Rx List, 2014b). Because human stroke patients receiving statins do not experience
these complications, it is thought that the amount of tPA produced in conjunction with
our rat dose would equate to much less than that produced in conjunction with the normal
human dose. If this is the case, then it is unlikely that the amount of tPA produced would
be enough to initiate hemorrhagic transformation.
A more promising idea is that the hemorrhagic transformation involves the drug
combination’s mechanism of action that increases VEGF in the brain. VEGF is a
mediator of neurogenesis, neuroprotection, and angiogenesis after ischemia (Gaillard and
Mir, 2001). VEGF is one mediator released by oxygen-deprived cells. It binds to
receptors on endothelial cells and, in response, the associated vessels dilate and leak. The
endothelial cells respond to the VEGF signal by producing other mediators that aid in
degrading the vascular basement membrane and reorganizing the extracellular matrix,
among other events. This permits and encourages endothelial cell migration and,
ultimately, proliferation and assembly into new vasculature (Mayes, 2006).
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In addition to promoting neurogenesis by increasing BDNF levels, fluoxetine may
induce expression of VEGF (Gaillard and Mir, 2001). Simvastatin also upregulates
BDNF and VEGF (Wu et al, 2008). VEGF increases angiogenesis, and it is possible that
vessel leakage is occurring during the period of increased angiogenesis. One study
showed that VEGF given to rats shortly after stroke resulted in a hemorrhagic
transformation; however, VEGF given later after a stroke proved to be beneficial
(Zhang et al, 2000). If our drug combination, given early at 6-12 hours post-stroke, is
causing abnormally-early expression of VEGF and vessel leakage, it is possible that this
is the mechanism behind the hemorrhagic transformation observed in this study.
Our study used a 5 mg/kg dose of fluoxetine. This rat dose equates to a human
dose of approximately 40 mg/kg, which is moderate when reviewing the dose range of
20-80 mg for this drug (Rx List, 2014a). Our rat dose of 1 mg/kg dose of simvastatin
equates to a human dose of 10 mg, which is low in the dose range of 5-40 mg for this
drug (Rx List, 2014b). Because of this, it is possible that fluoxetine would contribute
more to the VEGF timing production issue. More research is needed to determine the
exact culprit behind the secondary hemorrhagic strokes observed in this study. Changing
the administration time of the drug combination to one already proven to be safe would
also be encouraged.
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FUTURE EXPERIMENTS
Many questions were raised during analysis of the data presented in this thesis.
Several possible future experiments are discussed.

Repeat This Study
The findings of this study suggest possible benefits with drug treatment alone,
rehabilitation alone, and a combination of the two variables. However, a secondary
hemorrhagic stroke may be occurring as a result of early drug delivery at 6-12 hours
post-stroke. An essential future study would be to repeat this study, analyzing
drug-treated animals and control animals in both rehabilitation and non-rehabilitation
groups with drug delivery at 6-12 hours post-stroke, with a larger sample size. By
redoing this study with increased sample sizes, it could be determined if our findings in
this study are consistent and if earlier drug delivery may in fact be causing the
hemorrhagic transformation. Steps could also be taken to measure endogenous tPA and
VEGF production to identify the exact culprit behind the secondary hemorrhagic strokes.

Drug Administration at 20-26 Hours Post-Stroke Plus Rehabilitation Component
It has been shown in previous studies from our laboratory that drug administration
at 20-26 hours post-stroke is beneficial and provides better results than earlier delivery at
6-12 hours post-stroke (Corbett et al, 2013). An important future study would be to
duplicate Experiment 2 from this study by comparing the four animal groups –
drug-treated and control animals in both rehabilitation and non-rehabilitation groups –
while providing drug administration at 20-26 hours instead of 6-12 hours post-stroke.
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This would revisit a successful administration timeline with the added rehabilitation
component and ideally eliminate the possible issue of secondary hemorrhagic stroke due
to too-early drug delivery.

Change Drug Duration
In our study, drug-treated animals continued receiving treatment for the full
length of the study. No investigation has been performed on determining the proper
duration of drug-treatment. Initiating future experiments to test different durations of
treatment would be valuable because it is unknown whether an animal’s recovery would
continue, plateau, or regress after the drug-treatment is stopped. It is also valuable
because, in human stroke patients, it would be necessary to know whether this treatment
would be temporary or permanent.

Lengthen Study to Better Determine Rehabilitative Effects
Animals in the rehabilitation group received rehabilitation beginning at poststroke day 8 for five-and-one-half weeks. While rehabilitation was occurring during the
Montoya testing for functional recovery at post-stroke days 29-31, rehabilitation had been
stopped already when tests were performed at post-stroke days 59-61 and 89-91.
Animals - even the control animals – appeared to retain functional recovery across the
duration of the study if they received rehabilitation, despite the fact that the rehabilitation
had been stopped much earlier (Figure 9). Additional studies conducted at longer length
would be beneficial to map whether functional recovery is retained or decreases after a
substantial amount of time.
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Measure Infarct Size Throughout Study
This study measured infarct volume at the end of the study using histological
analysis of the brain tissue. It would be interesting to measure infarct size at different
points throughout the study. One approach could involve inducing strokes in a large
sample size of animals followed by infarct analysis at different increments. For example,
brain tissue of one group of animals could be analyzed at 24 hours post-stroke to
understand the initial infarct size. Another possible approach could involve infarct
measurement in the same animals at different times throughout the study by using
magnetic resonance imaging (MRI), as seen in other studies (Christoforidis et al, 2011).

Use of Other Stains
To examine if infarct size could be used as a good variable in measuring the
effects of our drug combination, a future experiment could employ the use of different
stains. While the Nissl stain allows normal neurons to be observed, other stains may
benefit future studies by helping to determine other neuronal states, such as neurons that
are functional as compared to those that have grown and made new connections but are
not yet functional.

Employing Somatosensory Tests
The experiments examined in this thesis were completed using functional
behavioral tests to measure the effects of the stroke and, later, our drug combination on
functional – that is, motor – recovery. No analysis was done to also analyze effects of the
stroke and our drug treatment on somatosensory behavior. It would be interesting to
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employ the use of an added behavioral somatosensory test to determine if a
somatosensory deficit is present in addition to a motor deficit. This could give insight
precisely as to how the larger infarcts observed in this thesis study affected the animals’
brains. If a large infarct greatly affected somatosensory areas, this could provide
implications as to why little functional motor deficit was detected. Additionally, an
animal with impaired somatosensory function may have intact motor function, but it
would have difficulty grasping the sucrose pellets if it cannot feel or smell them. Adding
a somatosensory component to the study may help answer the question presented earlier
in this section regarding heterogeneity in damage.

CONCLUSIONS
Differences in functional recovery across groups suggest several possible
treatment options. Without rehabilitation, drug treatment provides better functional
recovery (Figure 13). This proposes that drug treatment alone to be an option, which is
beneficial because patients incapable of performing physical therapy could still have
hope for recovery. With rehabilitation, there was no difference in functional recovery
between drug-treated and control animals, suggesting rehabilitation – regardless of drug
administration – may provide an opportunity for recovery (Figure 14). If rehabilitation
alone is an option, this could help patients with pharmaceutical restrictions.
Rehabilitation also provides the opportunity for greater recovery even in the occurrence
of larger infarcts (Figure 15), which may be beneficial to hemorrhagic stroke patients.
Finally, drug treatment combined with rehabilitation may initiate faster recovery early on
(Figure 9), but further investigation is needed.
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The issue of heterogeneity in damage raises questions of whether the forelimb
motor cortex alone was affected. With possible somatosensory areas involved, especially
with the larger infarct volumes, additional parameters such as somatosensory testing
could be employed in future studies.
Larger infarcts presented in this study with earlier drug delivery at 6-12 hours
post-stroke may be the result of hemorrhagic transformation due to a too-early induction
of VEGF expression by our drug combination. Further exploration into the mechanisms
involved is necessary, as is duplicating this study and performing new experiments at the
later drug delivery of 20-26 hours post-stroke.
Ultimately, further investigation is needed to increase sample size to better
quantify the results. Additional research will also aid in properly measuring the effects of
our drug combination on functional recovery and infarct size, the timing of drug delivery,
and the effects of limb rehabilitation on functional recovery.
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